Processes for making bicyclic ketone compounds

A novel multi-step process for synthesizing chiral bicyclic ketone compounds addresses the synthesis challenges of RIP1 kinase inhibitors, enhancing yield and purity through halogenation, acid addition, and recrystallization, resulting in improved crystalline forms.

WO2026236344A1PCT designated stage Publication Date: 2026-11-12GENENTECH INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026876
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The synthesis of RIP1 kinase inhibitors, particularly stereoisomers, is challenging, and there is a need for new synthetic procedures to produce these compounds effectively.

Method used

A multi-step process involving halogenation, acid addition, imidate compound interaction, organometallic compound reaction, and recrystallization is employed to produce chiral bicyclic ketone compounds, including cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone, with specific X-ray powder diffraction patterns.

Benefits of technology

The process achieves improved yield, product purity, diastereomeric ratio, and stereomeric excess, avoiding racemization events, and results in crystalline forms with distinct diffraction patterns.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026876_12112026_PF_FP_ABST
    Figure US2026026876_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Processes are provided herein for the preparation of a bicyclic ketone compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, and n are as defined herein; and compounds prepared by these processes.
Need to check novelty before this filing date? Find Prior Art

Description

PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 802,033, filed May 8, 2025, the disclosure of which is incorporated herein by reference in its entirety.FIELD OF INVENTION

[0002] Provided herein are processes of making bicyclic ketone compounds useful for therapy and / or prophylaxis in a mammal, in addition to compounds prepared by the processes.BACKGROUND

[0003] Receptor-interacting protein-1 (“RIP1”) kinase is a serine / threonine protein kinase. RIP1 is a regulator of cell signaling that is involved, among other things, in the mediation of programmed cell death pathways, e.g., necroptosis. The best studied form of necroptotic cell death is initiated by TNFa (tumor necrosis factor), but necroptosis can also be induced by other members of the TNFa death ligand family (Fas and TRAIL / Apo2L), interferons, Tolllike receptors (TLRs) signaling and viral infection via the DNA sensor DAI (DNA-dependent activator of interferon regulatory factor). Binding of TNFa to the TNFR1 (TNF receptor 1) prompts TNFR1 trimerization and formation of an intracellular complex, Complex-I. TRADD (TNF receptor associated death domain protein) binds to the intracellular death domain of TNFR1 and recruits the protein kinase RIP1 (receptor-interacting protein 1) through the death domain present in both proteins. Following initial recruitment into TNFR1-associated signaling complex, RIP1 translocates to a secondary cytoplasmatic complex, Complex-ll. Complex-ll is formed by the death domain containing protein FADD (Fas-associated Protein), RIP1, caspase-8 and cFLIP. If caspase-8 is not fully activated or its activity is blocked, the protein kinase RIP3 gets recruited to the complex, forming a necrosome, which will lead to necroptotic cell death initiation. Once the necrosome is formed, RIP1 and RIP3 engage in a series of auto and cross phosphorylation events that are essential for necroptotic cell death. Necroptosis can be completely blocked either by the kinase inactivating mutation in any of the two kinases, or chemically by RIP1 kinase inhibitors (necrostatins), or RIP3 kinase inhibitors. Phosphorylation of RIP3 allows the binding and phosphorylation of pseudokinase MLKL (mixed lineage kinase domain-like), a key component of necroptotic cell death.

[0004] Necroptosis has crucial pathophysiological relevance in myocardial infarction, stroke, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel diseases, retinal degeneration and a number of other common clinical disorders. Therefore, selective inhibitors of RIP1 kinase activity are therefore desired as a potential treatment of diseases mediated by this pathway and associated with inflammation and / or necroptotic cell death.

[0005] Inhibitors of RIP1 kinase have been previously described. The first published inhibitor of RIP1 kinase activity was necrostatin 1 (Nec-1). This initial discovery was followed by modified versions of Nec-1 with various abilities to block RIP1 kinase activity. Recently, additional RIP1 kinase inhibitors have been described that differ structurally from necrostatin class of compounds (International Patent Publication No. WO 2014 / 125444 and WO 2017 / 004500).

[0006] Synthesis of the inhibitors, including, for example, particular stereoisomers, is difficult. There is accordingly a need for new synthetic procedures for making the inhibitors.SUMMARY

[0007] Provided herein are solution to these problems and more.

[0008] In one aspect, processes are provided herein for the preparation of a chiral bicyclic ketone compound of formula (I):2or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, C1-C6 haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom and R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)Ci-Ce alkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl);each RNis independently selected from the group consisting of H, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkyl; or two RNmay together with the adjacent N form a 4-6 membered ring;R2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce thioalkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), CH2CH2-(C3-Ce cycloalkyl), CH2-(4 to 6 membered heterocyclyl), CH2CH2-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); wherein when a phenyl ring is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and cyano;n is 1, 2 or 3.

[0009] In another aspect, processes are provided herein for preparation of a chiral bicyclic ketone compound of formula (1-1):or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce haloalkyl, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom and R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, hydroxyl, hydroxymethyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); each R4is selected from the group consisting of D, F, Cl, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy and Ci-Ce haloalkoxy;n is 1, 2 or 3;m is 0, 1, 2, or 3;the process comprising:(a) contacting a compound of formula (11-1):(H-1)or a salt thereof, with a halogenating agent to form a compound of formula (111-1):For a salt thereof,(b) contacting the compound of formula (111-1) or the salt thereof, with a first acid additive to form a compound of formula (IV-1 ):For a salt thereof;(c) contacting the compound of formula (IV-1) or the salt thereof, with an imidate compound of formula (V):or a salt thereof, to form a chiral bicyclic triazole compound of formula (VI-1):For a salt thereof;(d) contacting the chiral bicyclic triazole compound of formula (VI-1), or the salt thereof with a compound R11-H, or a salt thereof in the presence of a basic additive to form a compound of formula (VI 1-1):For a salt thereof;(e) contacting the chiral bicyclic acyl compound of formula (VII-1), or salt thereof with an organometallic compound of formula (VIII):R1—M(VIII)to form the chiral bicyclic ketone compound of formula (1-1), or the pharmaceutically acceptable salt thereof;(f) dissolving an initial amount the chiral bicyclic ketone compound of formula (1-1) in a recrystallizing solvent to provide a recrystallization slurry; and(g) adding portions of an anti-solvent to the recrystallization slurry until at least a portion of the chiral bicyclic ketone compound of formula (1-1) crystallizes in a crystalline form;wherein:Pg1is H or a hydroxyl protecting group and may be the same or different on each occurrence;Pg2is a nitrogen protecting group and may be the same or different on each occurrence;R11is -NR51R52or 5- to 6-membered heterocyclyl optionally subsituted with one or more R6groups, whereinR51is H, Ci-Ce alkyl optionally substituted with one or more R53groups, or Ci- Ce cycloalkyl optionally substituted with one or more R54groups,R52is Ci-Ce alkyl optionally substituted with one or more R55groups, or Ci-Ce alkoxy optionally substituted with one or more R56groups, wherein each R53and R54is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; andeach R55and R56is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy;each R6is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; and M is lithium, MgX1, or ZnX2, wherein X1and X2are each halide or R1, or a mixture thereof.

[0010] In another aspect, compounds are provided herein prepared by the processes described herein.

[0011] In another aspect, the disclosure provides a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern with peaks of at least about 7.5° 20, about 8.2° 20, about 18.2° 20, about 20.0° 20, about 24.5° 20, and about 25.7° 20.

[0012] In another aspect, the disclosure provides a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern with peaks of at least about 11.2° 20, about 13.8° 20, about 14.9° 20, about 17.6 ° 20, about 19.7 ° 20, about 20.3 ° 20, about 22.6 ° 20, and about 24.4° 20.

[0013] The subject methods provide unexpectedly better overall yield in producing compounds of formula (I) or formula (1-1) or pharmaceutically acceptable salts thereof, as well as improved product purity, improved diastereomeric ratio, improved stereomeric excess, via avoidance of potential racemization events, and improved yield. Additional embodiments and details are provided below.BRIEF DESCRIPTION OF THE DRAWINGS

[0014] FIG. 1 depicts Raman spectra of crystalline forms of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone.

[0015] FIG. 2 depicts x-ray powder diffraction patterns of crystalline form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone.

[0016] FIG. 3 depicts x-ray powder diffraction patterns of crystalline form B of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone.

[0017] FIG. 4 depicts thermogravimetric analysis and differential scanning calorimetry curves for a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1 ,2-b][1 ,2,4]triazol-2-yl)methanone.

[0018] FIG. 5 depicts thermographic analysis and differential scanning calorimetry curves for a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone.DETAILED DESCRIPTION

[0019] As provided herein, all chemical formulae and generic chemical structures should be interpreted to provide proper valence and chemically stable bonds between atoms as understood by one of ordinary skill in the art. Where appropriate, substituents may be bonded to more than one adjacent atom (e.g., alkyl includes methylene where two bonds are present).

[0020] In the chemical formulae provided herein, “halogen” or “halo” refers to fluorine, chlorine, and bromine ( / .e., F, Cl, Br).

[0021] “Alkyl”, unless otherwise specifically defined, refers to an optionally substituted, straight-chain or branched C1-C12 alkyl group. In some embodiments, “alkyl” refers to a C1-Ce alkyl group. Exemplary alkyl groups include methyl, ethyl, propyl, / so-propyl, n-butyl, / so-butyl, terf-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl. Substituted alkyl groups provided herein are substituted by one or more substituents selected from the group consisting of halogen, cyano, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, C3-C6 cycloalkyl, phenyl, OH, CO2H, CO2(Ci-C4 alkyl), NH2, NH(CI-C4 alkyl), N(CI-C4alkyl)2, NH(C=O)CI-C4alkyl, (C=O)NH(CI-C4alkyl), (C=O)N(CI-C4alkyl)2, S(Ci-C4alkyl), SO(Ci-C4alkyl), SO2(Ci-C4alkyl), SO2NH(CI-C4alkyl), SO2N(CI-C4alkyl)2, and NHSO2(CI-C4 alkyl). In some embodiments, the substituted alkyl group has 1 or 2 substituents. In some embodiments, the alkyl group is unsubstituted.

[0022] “Cycloalkyl”, unless otherwise specifically defined, refers to an optionally substituted C3-C12 cycloalkyl group and includes fused, spirocyclic, and bridged bicyclic groups, wherein the substituents are selected from the group consisting of halogen, cyano, trifluoromethyl,methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, C3-C6 cycloalkyl, phenyl, OH, CO2H, CO2(Ci-C4alkyl), NH2, NH(CI-C4alkyl), N(CI-C4alkyl)2, NH(C=O)CI-C4alkyl, (C=O)NH(Ci-C4alkyl), (C=O)N(CI-C4alkyl)2, S(Ci-C4alkyl), SO(Ci-C4alkyl), SO2(Ci-C4alkyl), SO2NH(CI-C4alkyl), SO2N(CI-C4alkyl)2, and NHSO2(CI-C4alkyl). In some embodiments, cycloalkyl refers to a C3-C6 cycloalkyl group. In some embodiments, the C3-C6 cycloalkyl group is optionally substituted with 1 to three halogen atoms. In some embodiments, the C3-C6 cycloalkyl group is optionally substituted with 1 to three fluorine atoms. Exemplary C3-C6 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Exemplary C3-Ci2cycloalkyl groups further include bicyclo[3.1.0]hexyl, bicyclo[2.1.1]hexyl, cycloheptyl, bicycle[4.1.0]heptyl, spiro[4.2]heptyl, cyclooctyl, spiro[4.3]octyl, spiro[5.2]octyl, bicyclo[2.2.1]heptanyl, bicycle[2.2.2]octanyl, adamantanyl, decalinyl, and spiro[5.4]decanyl. Where appropriate, cycloalkyl groups may be fused to other groups such that more than one chemical bond exists between the cycloalkyl group and another ring system (e.g., the C ring of formula I). In some embodiments, the cycloalkyl group is unsubstituted.

[0023] “Haloalkyl”, unless otherwise specifically defined, refers to a straight-chain or branched Ci-Ci2alkyl group, wherein one or more hydrogen atoms are replaced by a halogen. In some embodiments, “haloalkyl” refers to a Ci-Ce haloalkyl group. In some embodiments, 1 to 3 hydrogen atoms of the haloalkyl group are replaced by a halogen. In some embodiments, every hydrogen atom of the haloalkyl group is replaced by a halogen (e.g., trifluoromethyl). In some embodiments, the haloalkyl is as defined herein wherein the halogen in each instance is fluorine. Exemplary haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, and pentafluoroethyl.

[0024] “Alkoxy”, unless otherwise specifically defined, refers to a straight-chain or branched Ci-Ci2alkyl group, wherein one or more oxygen atoms are present, in each instance between two carbon atoms. In some embodiments, “alkoxy” refers to a Ci-Ce alkoxy group. In some embodiments, Ci-Ce alkoxy groups provided herein have one oxygen atom.Exemplary alkoxy groups include methoxy, ethoxy, CH2OCH3, CH2CH2OCH3, CH2OCH2CH3, CH2CH2OCH2CH3, CH2OCH2CH2CH3, CH2CH2CH2OCH3, CH2OCH(CH3)2, CH2OC(CH3)3, CH(CH3)OCH3, CH2CH(CH3)OCH3, CH(CH3)OCH2CH3, CH2OCH2OCH3, CH2CH2OCH2CH2OCH3, and CH2OCH2OCH2OCH3.

[0025] “Haloalkoxy”, unless otherwise specifically defined, refers to a Ci-Ce haloalkyl group as defined above, wherein one or two oxygen atoms are present, in each instance between two carbon atoms. In some embodiments, Ci-Ce haloalkoxy groups provided herein have one oxygen atom. Exemplary haloalkoxy groups include OCF3, OCHF2and CH2OCF3.

[0026] “Thioalkyl”, unless otherwise specifically defined, refers to a C1-C12 or a Ci-Ce alkoxy group as defined above wherein the oxygen atom is replaced by a sulfur atom. In some embodiments, thioalkyl groups may include sulfur atoms substituted by one or two oxygen atoms (i.e. , alkylsulfones and alkyl sulfoxides). Exemplary thioalkyl groups are those exemplified in the definition of alkoxy above, wherein each oxygen atom is replaced by a sulfur atom in each instance.

[0027] “Heterocyclyl”, unless otherwise specifically defined, refers to a single saturated or partially unsaturated 4 to 8 membered ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such saturated or partially unsaturated ring, which multiple condensed ring systems have from 7 to 12 atoms and are further described below. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6, 7 or 8 membered rings) from about 1 to 7 carbon atoms and from about 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be C-branched (i.e., substituted by C1-C4 alkyl). The ring may be substituted with one or more (e.g., 1 , 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Exemplary heterocycles include but are not limited to azetidinyl, tetrahydrofuranyl and piperidinyl. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heterocycle) can be at any position of the multiple condensed ring system. It is also to be understood that the point of attachment for a heterocycle or heterocycle multiple condensed ring system can be at any suitable atom of the heterocyclyl group including a carbon atom and a nitrogen atom. Exemplary heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,2, 3, 4- tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1 ,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, spiro[cyclopropane-1,1'-isoindolinyl]-3'-one, isoindolinyl-1-one, 2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one N-methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, 1,4-dioxane, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, pyran, 3-pyrroline, thiopyran, pyrone, tetrhydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane,(1R,5S)-3-azabicyclo[3.2.1]octane, (1s,4s)-2-azabicyclo[2.2.2]octane, (1 R, 4 R) -2- oxa- 5-azabicyclo[2.2.2]octane and pyrrolidin-2-one.

[0028] In some embodiments, the heterocyclyl is a C4-C10 heterocyclyl having 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In some embodiments, the heterocyclyl group is neither bicyclic nor spirocyclic. In some embodiments, the heterocyclyl is a Cs-Ce heterocylcyl having 1 to 3 heteroatoms, wherein at least 2 are nitrogen if 3 heteroatoms are present.

[0029] “Aryl”, unless otherwise specifically defined, refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic and wherein the aryl group has 6 to 20 carbon atoms, 6 to 14 carbon atoms, 6 to 12 carbon atoms, or 6 to 10 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e. , carbocycle). Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the point of attachment of a multiple condensed ring system, as defined above, can be at any position of the ring system including an aromatic or a carbocycle portion of the ring. Exemplary aryl groups include phenyl, indenyl, naphthyl, 1, 2, 3, 4-tetrahydronaphthyl, anthracenyl, and the like.

[0030] “Heteroaryl”, unless otherwise specifically defined, refers to a 5 to 6 membered aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multiple condensed ring systems having 8 to 16 atoms that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2 or 3 rings) wherein a heteroaryl group, as defined above, is condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycles, (to form for example a 1, 2, 3, 4-tetrahydronaphthyridinyl such as 1,2,3,4-tetrahydro-1,8-naphthyridinyl), carbocycles (to form for example 5,6, 7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensedring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has 1 to 15 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system. It is also to be understood that the point of attachment for a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl or heteroaryl multiple condensed ring system including a carbon atom and a heteroatom (e.g., a nitrogen). Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-1H-indazole and 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclo-penta[1 ,2-c]pyrazole.

[0031] As used herein, the term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.

[0032] As used herein, the term “stereoisomers” refers to compounds which have identical chemical constitution but differ with regard to the arrangement of the atoms or groups in space.

[0033] As used herein a wavy linethat intersects a bond in a chemical structure indicates the point of attachment of the bond that the wavy bond intersects in the chemical structure to the remainder of a molecule.

[0034] “Enantiomers” refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

[0035] Stereochemical definitions and conventions used herein generally follow S. P.Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds,” John Wiley & Sons, Inc., New York, 1994. The compounds of the invention can contain asymmetric orchiral centers and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention. Many organic compounds exist in optically active forms, i.e. , they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and I or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer can also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which can occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

[0036] When a bond in a compound formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities. When a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge), it is to be understood that the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted unless otherwise noted. In one embodiment, the compound may be at least 51% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 80% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 97% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 98% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.

[0037] As used herein, the term “solvate” refers to an association or complex of one or more solvent molecules and a compound of the invention. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term “hydrate” refers to the complex where the solvent molecule is water. In some embodiments, a hydrate of a compound provided herein is a ketone hydrate.

[0038] As used herein, the term “protective group” or “protecting group” refers to a substituent that is commonly employed to block or protect a particular functional group on a compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include phenylsulfonylethyl, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see P.G.M. Wuts and T.W. Greene, Greene's Protective Groups in Organic Synthesis 4thedition, Wiley-lnterscience, New York, 2006.

[0039] As used herein, the term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic,or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M., et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0040] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

[0041] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention can exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0042] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention.

[0043] The term “composition”, as used herein, is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0044] In some embodiments, “stereomeric excess” as used herein refers to enantiomeric excess. “Enantiomeric excess” or “ee” are used interchangeably herein to refer to the degree to which a sample contains one enantiomer compared to its corresponding non-superimposable mirror compound. A racemic mixture has an ee of 0%, whereas a sample including only one enantiomer has an ee of 100%.

[0045] Provided herein are processes for the preparation of compounds useful in the treatment of diseases and disorders associated with inflammation, cell death, neurological disorders and other diseases. In some embodiments, the prepared compounds include inhibitors of RIP1 kinase useful in the treatment of such diseases and disorders. In some embodiments, the prepared compounds include compounds that are exemplified, for example, in U.S. Patent App. Publication US2019 / 0100530, the content of which is incorporated herein in its entirety. The processes described herein, for example, improve product purity, diastereomeric ratio (dr), stereomeric excess, and / or yield of the final products as well as key intermediates in the synthesis thereof. The processes described herein will be more fully understood with reference to the several reaction schemes below. In some embodiments, the processes unexpectedly provide improved product purity, improved diastereomeric ratio, improved stereomeric excess, and / or improved yield.Improved product purity includes, for example, improved chiral purity of the reaction product.

[0046] In some embodiments, processes are provided herein for the preparation of a compound of formula (I):2or pharmaceutically acceptable salts thereof, wherein:R1is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, C1-C6 haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom and R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)Ci-Ce alkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl);each RNis independently selected from the group consisting of H, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkyl; or two RNmay together with the adjacent N form a 4-6 membered ring;R2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce thioalkyl, phenyl, benzyl, CH2- (C3-C6 cycloalkyl), CH2CH2-(C3-Ce cycloalkyl), CH2-(4 to 6 memberedheterocyclyl), CH2CH2-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); wherein when a phenyl ring is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and cyano; andn is 1, 2 or 3.

[0047] In certain embodiments, processes are provided herein for the preparation of a compound of formula (I), or a salt thereof, wherein R1is Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, phenyl, benzyl, 4 to 8 membered heterocyclyl, or 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom. In certain embodiments, R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)Ci-Ce alkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl). In certain embodiments, R1is C3-C6 cycloalkyl optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)Ci-Ce alkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl). In certain embodiments, R1is cyclopropyl optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)Ci-Ce alkyl, phenyl, benzyl, CH2-(C3-C6cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl). In certain embodiments, R1is cyclopropyl.

[0048] In certain embodiments, processes are provided herein for the preparation of a compound of formula (I), or a salt thereof, wherein R2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce thioalkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), CH2CH2-(C3-Ce cycloalkyl), CH2-(4 to 6 membered heterocyclyl), CH2CH2-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); wherein when a phenyl ring is present it may be substituted by 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and cyano.

[0049] In certain embodiments, R2is Ci-Ce alkyl, e.g., ethyl, isopropyl, or n-propyl. In certain embodiments, R2is Ci-Ce haloalkyl, e.g., trifluoromethyl, 1,1 -difluoroethyl, or 1,1,-difluoropropyl. In certain embodiments, R2is phenyl optionally substituted with 1, 2, or 3independently selected R4substituents, wherein each R4is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and cyano. For example, in certain embodiments, processes are provided herein for the preparation of a compound selected from the group consisting of formulae (1-1) to (I-7):F F F0 N. _ J0°RiJ y^ .z -^ KIR1(I-2) (I-3)(1-1)F F F00 0z v KI yR M< N T-NV y]nfR1 N-NVfZ ^FfF(I-5)(I-4)(I-6)F0M T yR<}nCF3(I-7)wherein R1and n are as defined herein, m is 0, 1, 2, or 3; and each R4is halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and cyano.

[0050] In certain embodiments, processes are provided herein for the preparation of a compound of formula (I) or (1-1) wherein the compound is flizasertib (cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1 ,2-b][1 ,2,4]triazol-2-yl)methanone); CAS Registration No. 2268739-68-8), having the structure:or a pharmaceutically acceptable salt thereof.

[0051] 11 n some embodiments, a process is provided herein for the preparation of a chiral bicyclic ketone compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, and n are as defined herein, the process comprising:(e) contacting a chiral bicyclic acyl compound of formula (VII):2(VII)or a salt thereof, with an organometallic compound of formula VIII:R1— M(VIII)to form the chiral bicyclic ketone compound of formula (I), or the pharmaceutically acceptable salt thereof;wherein:R11is -NR51R52or 5- to 6-membered heterocyclyl optionally substituted with one or more R6groups, whereinR51is H, Ci-Ce alkyl optionally substituted with one or more R53groups, or Ci- Ce cycloalkyl optionally substituted with one or more R54groups,R52is Ci-Ce alkyl optionally substituted with one or more R55groups, or Ci-Ce alkoxy optionally substituted with one or more R56groups, wherein each R53and R54is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; andeach R55and R56is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy;each R6is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; and M is lithium, MgX1, orZnX2, whereinX1and X2are each halide or R1, or a mixture thereof.

[0052] In certain embodiments, contacting a chiral bicyclic acyl compound of formula (VII) or a salt thereof is in a solvent. In certain embodiments, the solvent is an ether solvent. In certain embodiments, the solvent is in 2-methyltetrahydrofuran (2-MeTHF), tetrahydrofuran (THF), diethyl ether (Et2O), methyl tert-butyl ether (MTBE), cyclopropyl methyl ether (CPME),or 1,4-dioxane. In certain embodiments, the solvent is THF or Et2O. In certain embodiments, the solvent is THF. In certain embodiments, the solvent is Et2O.

[0053] In certain embodiments, R11is -NR51R52, wherein R51is Ci-Ce alkyl optionally substituted with one or more R53groups and R52is Ci-Ce alkyl optionally substituted with one or more R55groups. In certain embodiments, R51is methyl and R52is methoxy. In certain embodiments, R51and R52are both methyl.

[0054] In certain embodiments, R11is 5- to 6-membered heterocyclyl optionally substituted with one or more R6groups. In certain embodiments, the 5- to 6-membered heterocyclyl comprises a nitrogen that is bound to the carbonyl of formula (VII). In certain embodiments, the 5- to 6-membered heterocyclyl further comprises an oxygen atom. For example, in certain embodiments, R11is:H3CC) 13-hr7’6H3

[0055] In certain embodiments, M is lithium. In certain embodiments, M is MgX1, wherein X1is halide or R1, or a mixture thereof. The person of ordinary skill in the art will recognize that compounds of formula (VIII) wherein M is MgX1can exist in a Schlenk equilibrium, wherein X1exists as an equilibrium mixture between halide and R1. In certain embodiments, M is ZnX2, wherein X2is halide or R1, or a mixture thereof. In certain embodiments, M is MgX1, wherein X1is bromide or R1, or a mixture thereof, and R1is cyclopropyl.

[0056] The compound of formula (VIII) can be provided to step (e) as a solution. In certain embodiments, the solution of the compound of formula (VIII) comprises an ether solvent (e.g., 2-MeTHF, THF, Et20, MTBE, or 1,4-dioxane). In certain embodiments, the ether solvent of the solution and the fifth ether solvent are the same. In certain embodiments, the ether solvent of the solution and the fifth ether solvent are different. In certain embodiments, the solution of the compound of formula (VIII) has a concentration in the range of 0.5 M to 1.5 M, e.g., in the range of 0.5 M to 1.2 M, or in the range of 0.5 M to 1.0 M, or in the range of 0.5 M to 0.8 M, as determined by titration. The person of ordinary skill in the art will be familiar with methods of titrating organometallic reagents.

[0057] In certain embodiments, step (e) is performed at a reaction temperature in the range of -20 °C to 20 °C, e.g., in the range of -20 °C to 10 °C, or -20 °C to 5 °C, or -20 °C to 0 °C. In certain embodiments, step (e) is performed at a reaction temperature in the range of -10 °C to 20 °C, e.g. , in the range of -10 °C to 10 °C, or -10 °C to 5 °C, or -10 °C to 0 °C. In certain embodiments, step (e) is performed at a reaction temperature in the range of -5 °C to 20 °C, e.g., in the range of -5 °C to 10 °C, or -5 °C to 5 °C, or -5 °C to 0 °C.

[0058] In certain embodiments, step (e) is performed with a molar ratio of VIII to VII in the range of 0.8 to 2.0, e.g., in the range of 0.8 to 1.8, or in the range of 0.8 to 1.6, or in the range of 0.8 to 1.4. In certain embodiments, step (e) is performed with a molar ratio of VIII to VII in the range of 1.0 to 2.0, e.g., in the range of 1.0 to 1.8, or in the range of 1.0 to 1.6, or in the range of 1.0 to 1.4. In certain embodiments, step (e) is performed with a molar ratio of VIII to VII of about 1.2.

[0059] In some embodiments, a process is provided herein for the preparation of a chiral bicyclic ketone compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R2, R11, and n are as defined herein, the process further comprising:(d) contacting a chiral bicyclic triazole compound of formula (VI):For a salt thereof, with a compound R11-H or a salt thereof, in to form the chiral bicyclic acyl compound of formula (VII), or the salt thereof;wherein R11is as defined herein and Pg1is H or a hydroxyl protecting group and may be the same or different on each occurrence.

[0060] In certain embodiments of step (d), contacting a chiral bicyclic triazole compound of formula (Vl)is in an alcohol solvent, e.g., methanol, ethanol, or isopropanol. In certain embodiments, the solvent is a polar solvent, e.g., N,N-dimethylformamide (DMF) or N-methylpyrrolidone (NMP). In certain embodiments, the solvent is dichloromethane. In certain embodiments, the solvent is methanol.

[0061] In certain embodiments of step (d), Pg1is H, the solvent is a polar solvent or dichloromethane, and the contacting of the compound of formula (VI) and the compound R11-H is performed in the presence of a carboxyl-activating agent and an acylating agent. In certain embodiments, the carboxyl-activating agent is 3-ethyldicarbodiimide (EDCI). In certain embodiments, the acylating agent is 1-methyl imidazole (NMI), hexafluorophosphate azabenzotriazole tetramethyl uranium (HATLI), or hexafluorophosphate benzotriazole tetramethyl uranium (HBTLI). In certain embodiments the carboxyl-activating agent is EDCI and the acylating agent is NMI.

[0062] In certain embodiments of step (d), a molar ratio of carboxyl-activating agent to the compound of formula (VI) is in the range of 0.8-1.8, e.g., in the range of 0.8-1.6, or in the range of 0.8-1.4. In certain embodiments, a molar ratio of carboxyl-activating agent to the compound of formula (VI) is in the range of 1.0-1.8, e.g., in the range of 1.0-1.6, or in the range of 1.0-1.4. In certain embodiments, a molar ratio of acylating agent to the compound of formula (VI) is in the range of 0.5-1.5, e.g., in the range of 0.5-1.2, or in the range of 0.5-1.0. In certain embodiments, the molar ratio of acylating agent to the compound of formula (VI) is in the range of 0.8-1.5, e.g., in the range of 0.8-1.2, or in the range of 0.8-1.0.

[0063] In certain embodiments of step (d), Pg1is a hydroxyl protecting group (e.g., ethyl), and the contacting of the compound of formula (VI) and the compound R11-H is performed in the presence of a basic additive and an alcohol solvent (e.g., methanol). In certain embodiments, the basic additive comprises a cation (e.g., lithium, sodium, or potassium) and an alkoxide (e.g., methoxide, ethoxide, or isopropoxide). In certain embodiments, the cation is lithium. In certain embodiments, the alkoxide is methoxide. For example, in certain embodiments, the basic additive is lithium methoxide.

[0064] In certain embodiments, a molar ratio of basic additive to R11-H is in the range of 0.8-1.8, e.g., in the range of 0.8-1.6, or in the range of 0.8-1.4.

[0065] In certain embodiments of step (d), R11-H is morpholine. In certain embodiments, R11-H is N,O-dimethylhydroxylamine. In certain embodiments of step (d), R11-H is provided as a salt, e.g., a hydrochloride salt. For example, in certain embodiment of step of step (d), R11-H is N,O-dimethylhydroxylamine hydrochloride.

[0066] In certain embodiments of step (d), a molar ratio of the compound of formula (VI) to R11-H is in the range of 0.8-1.8, e.g., in the range of 0.8-1.6, or in the range of 0.8-1.4. In certain embodiments of step (d), a molar ratio of the compound of formula (VI) to R11-H is in the range of 1.0-1.8, e.g., in the range of 1.0-1.6, or in the range of 1.0-1.4.

[0067] In some embodiments, a process is provided herein for the preparation of a chiral bicyclic ketone compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R2, Pg1and n are as defined herein, the process further comprising:(c) contacting a compound of formula (IV):For a salt thereof, with an imidate compound of formula (V):NH(V)or a salt thereof, in the presence of a second acid additive to form the bicyclic triazole compound of formula (VI), or salt thereof.

[0068] In certain embodiments of step (c), contacting a compound of formula (IV) is in a presence of solvent. In certain embodiments, the solvent is an alcohol solvent, e.g., methanol, ethanol or isopropanol. In certain embodiments of step (c), the solvent is ethanol.

[0069] In certain embodiments of step (c), the second acid additive is an organic acid. In certain embodiments of step (c), the second acid additive is acetic acid.

[0070] In certain embodiments of step (c), a molar ratio of the second acid additive to the compound of formula (IV) is in the range of 1.0 to 4.0, e.g., in the range of 1.5 to 4.0, or in the range of 2.0 to 4.0, or in the range of 2.5 to 4.0. In certain embodiments of step (c), a molar ratio of the second acid additive to the compound of formula (IV) is in the range of 1.0 to 3.5, e.g., in the range of 1.5 to 3.5, or in the range of 2.0 to 3.5, or in the range of 2.5 to 3.5.

[0071] In certain embodiments of step (c), at least one Pg1of the imidate compound of formula (V) is a hydroxyl protecting group, e.g., ethyl. In certain embodiments of step (c), both Pg1of the imidate compound of formula (V) are independently hydroxyl protecting groups, e.g., ethyl. For example, in certain embodiments of step (c), the imidate compound of formula (V) is ethyl 2-ethoxy-2-iminoacetate.

[0072] In certain embodiments of step (c), a molar ratio of the compound of formula (V) to the compound of formula (IV) is in the range of 1.0 to 2.0, e.g., in the range of 1.0 to 1.7. In certain embodiments of step (c), a molar ratio of the compound of formula (V) to the compound of formula (IV) is in the range of 1.2 to 2.0, e.g., in the range of 1.2 to 1.7.

[0073] In certain embodiments of step (c), step (c) is performed at a reaction temperature in the range of 40 °C to 100 °C, e.g., in the range of 50 °C to 100 °C, or in the range of 70 °C to 100 °C, or in the range of 70 °C to 100 °C. In certain embodiments of step (c), step (c) is performed at a reaction temperature in the range of 40 °C to 90 °C, e.g., in the range of 50 °C to 90 °C, or in the range of 70 °C to 90 °C, or in the range of 70 °C to 90 °C. In certain embodiments of step (c), step (c) is performed at a reaction temperature of about 80 °C.

[0074] In some embodiments, a process is provided herein for the preparation of a chiral bicyclic ketone compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R2, Pg2and n are as defined herein, the process further comprising:(b) contacting a compound of formula (III):For a salt thereof with a first acid additive or a second organic base to form the compound of formula (IV), or the salt thereof;wherein Pg2is a nitrogen protecting group and may be the same or different on each occurrence.

[0075] In certain embodiments of step (b), Pg2is a tert-butyloxycarbonyl protecting group (Boc), and the compound of formula (III) is contacted with a first acid additive. In certain embodiments, the first acid additive is hydrochloric acid. In certain embodiments, the first acid additive is trifluoroacetic acid (TFA). In certain embodiments, the first acid additive is provided as a solution in a solvent comprising an alcohol solvent (e.g., methanol, ethanol, or n-propanol), DCM, or toluene. In certain embodiments, the first acid additive is hydrochloric acid, provided as a solution in n-propanol.

[0076] In certain embodiments of step (b), contacting the compound of formula (111-1) or a salt thereof, is in a solvent. In certain embodiments, the solvent is an ether solvent (e.g., 2-MeTHF, Et20, MTBE, orCPME), an alcohol solvent (e.g., methanol, ethanol, isopropanol, or n-propanol), DCM, or toluene. In certain embodiments, the solvent is toluene.

[0077] In certain embodiments of step (b), step (b) is performed at a reaction temperature in the range of 0 °C to 30 °C, e.g., in the range of 0 °C to 25 °C, or 0 °C to 20 °C, or 0 °C to 15 °C, or 0 °C to 10 °C. In certain embodiments, step (b) is performed at a reaction temperature in the range of 5 °C to 30 °C, e.g., in the range of 5 °C to 25 °C, or 5 °C to 20 °C, or 5 °C to 15 °C.

[0078] In some embodiments, a process is provided herein for the preparation of a chiral bicyclic ketone compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R2, Pg2and n are as defined herein, the process further comprising:(a) contacting a compound of formula (II):OHnor a salt thereof, with a fluorinating agent to form the compound of formula (III), or the salt thereof.

[0079] Examples of fluorinating agents are described by M.K. Nielsen et al. in J. Am. Chem. Soc. 140(15):5004-5008 (2018).

[0080] In certain embodiments of step (a), the fluorinating agent isClMeCF3-C6H4SO2F, 4-NO2-C6H4SO2F, 4-CH3-C6H4SO2F, 2-NO2-C6H4SO2F, perfluorobutanesulfonyl fluoride, N-tosyl-4-chlorobenzenesulfonimidoyl fluoride, tetramethylfluoroformamidinium hexafluorophosphate, diethylaminosulfur trifluoride, bis(2-methoxyethyl)aminosulfur trifluoride, phenylmethyl sulfonyl fluoride, difluoro(morpholino)sulfonium tetrafluoroborate, or (diethylamino)difluorosulfonium difluorosulfinium tetrafluoroborate. In certain embodiments, the fluorinating agent is 2-pyridinesulfonyl fluoride. In certain embodiments, the fluorinating agent is 5-chloro-2-pyridinesulfonyl fluoride.

[0081] In certain embodiments of step (a), a molar ratio of the fluorinating agent to the compound of formula (II) is in the range of 0.8 to 2.0, e.g., in the range of 0.8 to 1.8, or in the range of 0.8 to 1.6, or in the range of 0.8 to 1.4. In certain embodiments, a molar ratio of the fluorinating agent to the compound of formula (II) is in the range of 1.0 to 2.0, e.g., in the range of 1.0 to 1.8, or in the range of 1.0 to 1.6, or in the range of 1.0 to 1.4.

[0082] In certain embodiments of step (a), the contacting of the compound of formula (II) and the fluorinating agent is performed in the presence of a first organic base. In certain embodiments, the organic base is triethylamine, N,N-diisopropylethylamine, 4-methylmorpholine, 1 ,8-diazabicyclo[5.4.0]undec-7-ene, 2-terf-buty I- 1 , 1 ,3,3-tetramethylguanidine, or 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene. In certain embodiments, the first organic base is triethylamine or N,N-diisopropylethylamine. In certain embodiments, the first organic base is trimethylamine.

[0083] In certain embodiments of step (a), the contacting of the compound of formula (II) and the fluorinating agent is performed in the presence of a fluoride source additive. In certain embodiments, the fluoride source additive is selected from triethylamine trihydrofluoride, cesium fluoride, N,N-diisopropylethylamine trihydrofluoride, pyridine hydrofluoride, tetrabutylammonium difluorotriphenylsilicate, and tetrabutylammonium fluoride. In certain embodiments, the fluoride source additive is triethylamine trihydrofluoride.

[0084] In certain embodiments of step (a), the contacting of the compound of formula (II) and the fluorinating agent is performed in the presence of a first organic base and a fluoride source additive, wherein the first organic base and the fluoride source additive are as defined herein. For example, in certain embodiments, the first organic base is trimethylamine and the fluoride source additive is triethylamine trihydrofluoride.

[0085] In certain embodiments of step (a), a molar ratio of the first organic base to the fluoride source additive is in the range of 1.0 to 2.0, e.g., in the range of 1.0 to 1.8. In certain embodiments, a molar ratio of the first organic base to the fluoride source additive is in the range of 1.2 to 2.0, e.g., in the range of 1.2 to 1.8. In certain embodiments, a molar ratio of the first organic base to the fluoride source additive is in the range of 1.4 to 2.0, e.g., in the range of 1.4 to 1.8.

[0086] In certain embodiments of step (a), contacting a compound of formula (II) or a salt thereof is in a solvent. In certain embodiments, the solvent is an ether solvent (e.g., 2-MeTHF, THF, Et2O, MTBE, or CPME) or toluene. In certain embodiments, the solvent is tetrahydrofuran. In certain embodiments, the solvent is Et2O. In certain embodiments, the solvent is toluene.

[0087] In certain embodiments of step (a), step (a) is performed at a reaction temperature in the range of 30 °C to 80 °C, e.g., in the range of 30 °C to 75 °C, or in the range of 30 °C to 70 °C, or in the range of 30 °C to 65 °C. In certain embodiments, step (a) is performed at a reaction temperature in the range of 40 °C to 80 °C, e.g., in the range of 40 °C to 75 °C, or in the range of 40 °C to 70 °C, or in the range of 40 °C to 65 °C.

[0088] In some embodiments, processes according to any one of preceding embodiments are provided herein for the preparation of flizasertib, such processes comprise:(a) contacting a compound of formula (II-2):0P Pgga22NNH(II-2)or a salt thereof, with a halogenating agent to form a compound of formula (HI-2):F0Pray2'NNHor a salt thereof,(b) contacting the compound of formula (111-2) or the salt thereof, with a first acid additive to form a compound of formula (IV-2):or a salt thereof;(c) contacting the compound of formula (IV-2) or the salt thereof, with an imidate compound of formula (V):or a salt thereof, to form a chiral bicyclic triazole compound of formula (VI-2):or a salt thereof;(d) contacting the chiral bicyclic triazole compound of formula (VI-2), or the salt thereof with a compound R11-H, or a salt thereof in the presence of a basic additive to form a compound of formula (VII-2):or a salt thereof;(e) contacting the chiral bicyclic acyl compound of formula (VI 1-2), or salt thereof with an organometallic compound of formula (VIII):> - M(VIII)to form flizasertib or the pharmaceutically acceptable salt thereof.

[0089] In some embodiments, a process is provided herein for the crystallization of a chiral bicyclic ketone compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1and n are as defined herein, the process comprising:adding at least a portion of a recrystallizing solvent to an initial amount the chiral bicyclic ketone compound of formula (I) to provide a recrystallization slurry; adding at least one portion of an anti-solvent to the recrystallization slurry until at least a portion of the chiral bicyclic ketone compound of formula (I) crystallizes in a crystalline form.

[0090] In certain embodiments of the process for the crystallization of the compound of formula (I), the recrystallization solvent is methanol, ethanol, isopropanol, n-butanol, acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), acetonitrile (MeCN),ethyl acetate (EtOAc), isopropyl acetate (iPrOAc), dimethyl sulfoxide (DMSO), DCM, chloroform, toluene, anisole, 2-MeTHF, THF, CPME, MTBE, or 1,4-dioxane. In certain embodiments, the recrystallization solvent is ethanol. In certain embodiments, the recrystallization solvent is acetone. In certain embodiments, the recrystallization solvent is EtOAc. In certain embodiments, the recrystallization solvent is MEK.

[0091] In certain embodiments of the process for the crystallization of the compound of formula (I), the anti-solvent is water, isopropanol, n-heptane, cyclohexane, CPME, or MTBE. In certain embodiments, the anti-solvent is water. In certain embodiments, the anti-solvent is n-heptane.

[0092] In certain embodiments of the process for the crystallization of the compound of formula (I), the recrystallization solvent is acetone and the anti-solvent is water.

[0093] In certain embodiments of the process for the crystallization of the compound of formula (I), the recrystallization solvent is EtOAc and the anti-solvent is n-heptane.

[0094] In certain embodiments of the process for the crystallization of the compound of formula (I), the recrystallization solvent is MEK and the anti-solvent is n-heptane.

[0095] In certain embodiments of the process for the crystallization of the compound of formula (I), the initial amount the chiral bicyclic ketone compound of formula (I) is dissolved in at least one portion of the recrystallizing solvent to provide a recrystallization slurry. In certain embodiments, the recrystallization solvent is added in one, two, three, or four portions. In certain embodiments, the recrystallization solvent is added in three portions.

[0096] In certain embodiments of the process for the crystallization of the compound of formula (I), at least one portion of the anti-solvent is added to the recrystallization solvent. In certain embodiments, one, two, three, or four portions of the anti-solvent are added to the recrystallization solvent. In certain embodiments, three portions of anti-solvent are added to the recrystallization solvent.

[0097] In certain embodiments of the process for the crystallization of the compound of formula (I), a weight ratio of a total amount of the recrystallization solvent added compared to a total amount of the anti-solvent added is in the range of 0.6 to 2.2, e.g., in the range of 0.6 to 2.0, or in the range of 0.6 to 1.8. In certain embodiments, a weight ratio of the recrystallization solvent to the anti-solvent is in the range of 1.0 to 2.2, e.g., in the range of 1.0 to 2.0, or in the range of 1.0 to 1.8. In certain embodiments, a weight ratio of the recrystallization solvent to the anti-solvent is in the range of 1.4 to 2.2, e.g., in the range of 1.4 to 2.0, or in the range of 1.4 to 1.8.

[0098] In certain embodiments of the process for the crystallization of the compound of formula (I), at least 50 wt% of the compound of formula (I) crystallizes in crystalline form, based on the initial amount of the dissolved compound of formula (I). In certain embodiments, at least 55 wt%, e.g., at least 60 wt%, or at least 65 wt%, or at least 70 wt%, or at least 75 wt% of the compound of formula (I) crystallizes in crystalline form, based on the initial amount of the dissolved compound of formula (I). In certain embodiments, 50 to 90 wt%, e.g., 55 to 90 wt%, or 60 to 90 wt%, or 65 to 90 wt%, or 70 to 90 wt%, or 75 to 90 wt% of the compound of formula (I) crystallizes in crystalline form, based on the initial amount of the dissolved compound of formula (I).

[0099] In certain embodiments of the process for the crystallization of the compound of formula (I), the process further comprises agitation of the recrystallization slurry. For example, in certain embodiments, the agitation of the recrystallization occurs in a wet milling slurry. In certain embodiments, the agitation of the recrystallization slurry is performed with a wet-milling frequency, at a wet-milling temperature, for a wet-milling time.

[0100] In certain embodiments, the wet-milling frequency is in the range of 10,000 to 30,000 rpm, e.g., in the range of 10,000 to 25,000 rpm, or in the range of 10,000 to 20,000 rpm. In certain embodiments, the wet-milling frequency is in the range of 12,000 to 30,000 rpm, e.g., in the range of 12,000 to 25,000 rpm, or in the range of 20,000 rpm. In certain embodiments, the wet-milling frequency is in the range of 15,000 to 30,000 rpm, e.g., in the range of 15,000 to 25,000 rpm, or in the range of 15,000 to 20,000 rpm.

[0101] In certain embodiments, the wet-milling temperature is in the range of 20 to 80 °C, e.g., in the range of 20 to 75 °C, or in the range of 20 to 70 °C, or in the range of 20 to 65 °C. In certain embodiments, the wet-milling temperature is in the range of 20 to 80 °C, e.g., in the range of 30 to 75 °C, or in the range of 30 to 70 °C, or in the range of 30 to 65 °C. In certain embodiments, the wet-milling temperature is in the range of 40 to 80 °C, e.g., in the range of 40 to 75 °C, or in the range of 40 to 70 °C, or in the range of 40 to 65 °C.

[0102] In certain embodiments, the wet-milling time is in the range of 3 to 14 hours, e.g., in the range of 3 to 12 hours, or in the range of 3 to 10 hours. The person of ordinary skill in the art will appreciate that a particular number of turnovers of the recrystallization slurry (i.e., the number of time the recrystallization slurry is circulated through the wet mill) can lead to a desired particle size distribution of the crystallized compound of formula (I). Accordingly, in certain embodiments, the wet-milling time is an amount of time sufficient for at least 5 turnovers, e.g., at least 10 turnovers, or at least 15 turnovers of the recrystallization slurry.

[0103] In certain embodiments of the process for the crystallization of the compound of formula (I), the process further comprises:adding seed crystals to the recrystallization slurry,wherein the seed crystals are the chiral bicyclic ketone compound of formula (I) in the crystalline form.

[0104] In certain embodiments of the process for the crystallization of the compound of formula (I), the seed crystals are added in an amount in the range of 1 to 10 wt%, e.g., in the range of 1 to 8 wt%, or in the range of 1 to 6 wt%, relative to the initial amount of the compound of formula (I). In certain embodiments, the seed crystals are added in an amount in the range of 2 to 10 wt%, e.g., in the range of 2 to 8 wt%, or in the range of 2 to 6 wt%, relative to the initial amount of the compound of formula (I).

[0105] In certain embodiments of the process for the crystallization of the compound of formula (I), the crystalline form of the compound of formula (I) is characterized in that it exhibits one or more features selected from:a Amax absorption in the range of 700 to 720 cm'1when subjected to Raman spectroscopy;peaks of at least about 7.8° 20, about 8.8° 20, about 15.2° 20, about 17.5° 20, about 20.5° 20, about 23° 20, and about 25.7° 20 when subjected to x-ray powder diffraction spectroscopy;the loss of no more than 0.5 wt% when subjected to thermal gravimetric analysis up to 150 °C; andan endothermic peak in the range of 159 to 162 °C when subjected to differential scanning calorimetry.In certain embodiments, the crystalline form of the compound of formula (I) exhibits one of the above features. In certain embodiments, crystalline form of the compound of formula (I) exhibits at least one of the above features (e.g., two, three, or four of the above features). In certain embodiments, crystalline form of the compound of formula (I) exhibits all of the above features.

[0106] In certain embodiments of the process for the crystallization of the compound of formula (I), the crystalline form of the compound of formula (I) is characterized in that it exhibits a Amax absorption in the range of 700 to 720 cm'1when subjected to Raman spectroscopy. In certain embodiments, the crystalline form of the compound of formula (I) is characterized in that it exhibits a Raman spectrum corresponding to the Raman spectrum shown in FIG. 1. The Blaze probe was connected to a Raman spectrometer with 785nm laser source (manufacturer: Tornado, model: Hyperflux Pro Plus Raman spectrometer). Foracquisition laser power was set at 495mW, for each spectra acquisition exposure time was 5sec, and number of acquisition for each final spectral output was set to 5.

[0107] In certain embodiments of the process for the crystallization of the compound of formula (I), the crystalline form of the compound of formula (I) is characterized in that it exhibits peaks of at least about 7.8° 20, about 8.8° 20, about 15.2° 20, about 17.5° 20, about 20.5° 20, about 23° 20, and about 25.7° 20 when subjected to x-ray powder diffraction (XRPD) spectroscopy. In certain embodiments, the crystalline form of the compound of formula (I) is characterized in that it exhibits a XRPD spectrum corresponding to the XRPD spectrum shown in FIG. 2. For XRPD analysis as used herein, PANalytical X-ray powder diffractometers were used in reflection mode. The XRPD parameters used are listed in Table 1:Table 1: Parameters for XRPD analysisParameters PANalyticalModel Empyrean X’ Pert3Cu, ka, Cu, ka,Ka1 (A): 1.540598, Ka1 (A): 1.540598, X-Ray wavelengthKa2 (A): 1.544426 Ka2 (A): 1.544426 Ka2 / Ka1 intensity ratio: 0.50 Ka2 / Ka1 intensity ratio: 0.50 X-Ray tube setting 45 kV, 40 mA 45 kV, 40 mA Divergence slit Automatic 1 / 8°Scan mode Continuous ContinuousScan range (°2TH) 3-40 3-40Scan step time (s) 17.8 46.7Step size (°2TH) 0.0167 0.0263Test Time (s) 5 min 30 s 5 min 04 s

[0108] In certain embodiments of the process for the crystallization of the compound of formula (I), the crystalline form of the compound of formula (I) is characterized in that it exhibits peaks listed in Table 2.Table 2: XRPD Peak ListingPos. [°20] Height [cts] FWHM Left [°20] d-spacing [A] Rel. Int. [%] 7.7833 35833.65 0.0886 11.34959 96.37 8.8174 7589.12 0.0886 10.02078 20.4115.1654 17452.72 0.1082 5.83751 46.94 17.4535 28194.93 0.1181 5.07702 75.83 17.6956 3664.80 0.0787 5.00813 9.86 18.3896 3792.22 0.0984 4.82066 10.20 18.7721 5379.31 0.1082 4.72327 14.47 19.7804 2243.77 0.1082 4.48473 6.03 20.4807 37183.56 0.1279 4.33294 100.00 21.0802 5297.46 0.1181 4.21104 14.25 22.9712 9351.18 0.1279 3.86849 25.15 23.5512 7607.22 0.1574 3.77452 20.46 24.3536 1667.28 0.0984 3.65194 4.48 25.4291 5192.94 0.1082 3.49986 13.97 25.6788 7700.35 0.1476 3.46640 20.71 26.3856 825.40 0.1771 3.37512 2.22 28.7000 3359.41 0.0886 3.10799 9.03 29.6799 5443.98 0.0787 3.00757 14.64 31.7641 1180.31 0.1574 2.81482 3.17 33.5694 2008.98 0.1574 2.66746 5.40 34.5338 1377.77 0.1378 2.59514 3.71 35.3136 1105.27 0.0984 2.53960 2.97 37.4184 612.85 0.1574 2.40145 1.65 38.8700 403.03 0.1574 2.31504 1.08

[0109] In certain embodiments of the process for the crystallization of the compound of formula (I), the crystalline form of the compound of formula (I) is characterized in that it exhibits loss of no more than 0.5 wt% when subjected to thermal gravimetric analysis (TGA) up to 150 °C.

[0110] In certain embodiments of the process for the crystallization of the compound of formula (I), the crystalline form of the compound of formula (I) is characterized in that itexhibits an endothermic peak in the range of 159 to 162 °C when subjected to differential scanning calorimetry (DSC). In certain embodiments, the crystalline form of the compound of formula (I) is characterized in that it exhibits a DSC graph corresponding to the DSC graph shown in FIG. 4.

[0111] As used herein, TGA data were collected using a TA Q500 / Q5000 / Q5500 TGA from TA Instruments. As used herein, DSC was performed using a TA Q200 / Q2000 / Q2500 DSC from TA Instruments using the detailed parameters used are listed in Table 3:Table 3: Parameters for TGA and DSC analysisParameters TGA DSC Method Ramp Ramp Sample pan Aluminum, open Aluminum, crimped Of* _ H cirprl Temprerature RT - desired temprerature . .temperatureH eati ng rate 10 °C / m in 10 °C / m i n Purge gas N2 N2

[0112] In another aspect, the disclosure provides for a compound of formula (I) provided from the processes disclosed herein. In another aspect, the disclosure provides for a compound of formula (I) in a crystalline form provided from the processes disclosed herein.

[0113] In another aspect, processes are provided herein for the preparation of a compound of formula (1-1):For pharmaceutically acceptable salts thereof, in a crystalline form, wherein:R1is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce haloalkyl, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom and R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl,Ci-Ce haloalkoxy, hydroxyl, hydroxymethyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); each R4is selected from the group consisting of D, F, Cl, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy and Ci-Ce haloalkoxy;n is 1, 2 or 3;m is 0, 1, 2, or 3;the process comprising:(a) contacting a compound of formula (11-1):or a salt thereof, with a halogenating agent to form a compound of formula (III- 1):For a salt thereof,(b) contacting the compound of formula (111-1), or the salt thereof, with a first acid additive or a second organic base to form a compound of formula (I V-1 ) :or a salt thereof;(c) contacting the compound of formula (IV-1 ) or the salt thereof, with an imidate compound of formula (V):° (V)or a salt thereof, to form a chiral bicyclic triazole compound of formula (VI-1):For a salt thereof;(d) contacting the chiral bicyclic triazole compound of formula (VI-1), or the salt thereof with a compound R11-H, or a salt thereof in the presence of a basic additive to form a compound of formula (VII-1):0 Nor a salt thereof;(e) contacting the chiral bicyclic acyl compound of formula (VII-1), or salt thereof with an organometallic compound of formula (VIII):R1—M(VIII)to form the chiral bicyclic ketone compound of formula (1-1), or the pharmaceutically acceptable salt thereof;(f) dissolving an initial amount the chiral bicyclic ketone compound of formula (1-1) in a recrystallizing solvent to provide a recrystallization slurry; and(g) adding portions of an anti-solvent to the recrystallization slurry until at least a portion of the chiral bicyclic ketone compound of formula (1-1) crystallizes in a crystalline form.wherein:Pg1is H or a hydroxyl protecting group and may be the same or different on each occurrence;Pg2is a nitrogen protecting group and may be the same or different on each occurrence;R11is -NR51R52or 5- to 6-membered heterocyclyl optionally subsituted with one or more R6groups, whereinR51is H, Ci-Ce alkyl optionally substituted with one or more R53groups, or Ci- Ce cycloalkyl optionally substituted with one or more R54groups, R52is Ci-Ce alkyl optionally substituted with one or more R55groups, or Ci-Ce alkoxy optionally substituted with one or more R56groups, wherein each R53and R54is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; andeach R55and R56is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy;each R6is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; and M is lithium, MgX1, orZnX2, whereinX1and X2are each halide or R1, or a mixture thereof.

[0114] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, R1, R4, m, n, R11, M, Pg1, and Pg2are as described herein for the process for providing the compound of formula (I).

[0115] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, steps (a), (b), (c), (d), and (e) are as described herein for the process for providing the compound of formula (I).

[0116] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, R1is cyclopropyl, n is 1, and m is 0. For example, in certain embodiments, the compound of formula (1-1) in a crystalline form is flizasertib (cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone); CAS Registration No. 2268739-68-8), having the structure:F

[0117] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, R11is:H3C6H3

[0118] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, Pg2is Boc.

[0119] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, Pg1is ethyl.

[0120] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, step (a) is performed in the presence of an organic base and a fluoride source additive. In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, step (a) is performed in the presence of a solvent. In certain embodiments, the solvent is tetrahydrofuran, the halogenating agent is 5-chloro 2-pyridinesulfonyl fluoride, the organic base is trimethylamine, and the fluoride source additive is trimethylamine trihydrofluoride.

[0121] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, step (b) of contacting the compound of formula (111-1) is performed in the presence of a solvent. In certain embodiments, the solvent is toluene, the first acid additive is hydrochloric acid.

[0122] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, contacting a compound of formula (I V-1 ) is in a presence of ethanol and the second acid additive is acetic acid.

[0123] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, contacting the chiral bicyclic triazole compound of formula (VI-1) is in methanol, and the basic additive is lithium methoxide.

[0124] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, contacting the chiral bicyclic acyl compound of formula (VII-1), or salt thereof is in a solvent that is tetrahydrofuran, M is MgX1, and X1is bromine.

[0125] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the recrystallization solvent is methanol, ethanol, isopropanol, n-butanol, acetone, methyl ethyl ketone (MEK), methyl isobutyl ketone (MIBK), acetonitrile (MeCN), ethyl acetate (EtOAc), isopropyl acetate (iPrOAc), dimethyl sulfoxide (DMSO), DCM, chloroform, toluene, anisole, 2-MeTHF, THF, CPME, MTBE, or 1,4-dioxane. In certainembodiments, the recrystallization solvent is ethanol. In certain embodiments, the recrystallization solvent is acetone. In certain embodiments, the recrystallization solvent is EtOAc. In certain embodiments, the recrystallization solvent is MEK.

[0126] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the anti-solvent is water, isopropanol, n-heptane, cyclohexane, CPME, or MTBE. In certain embodiments, the anti-solvent is water. In certain embodiments, the antisolvent is n-heptane.

[0127] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the recrystallization solvent is acetone and the anti-solvent is water.

[0128] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the recrystallization solvent is EtOAc and the anti-solvent is n-heptane.

[0129] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the recrystallization solvent is MEK and the anti-solvent is n-heptane.

[0130] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the initial amount the chiral bicyclic ketone compound of formula (I) is dissolved in at least one portion of the recrystallizing solvent to provide a recrystallization slurry. In certain embodiments, the recrystallization solvent is added in one, two, three, or four portions. In certain embodiments, the recrystallization solvent is added in three portions.

[0131] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, at least one portion of the anti-solvent is added to the recrystallization solvent. In certain embodiments, one, two, three, or four portions of the anti-solvent are added to the recrystallization solvent. In certain embodiments, three portions of anti-solvent are added to the recrystallization solvent.

[0132] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, a weight ratio of a total amount of the recrystallization solvent added compared to a total amount of the anti-solvent added is in the range of 0.6 to 2.2, e.g., in the range of 0.6 to 2.0, or in the range of 0.6 to 1.8. In certain embodiments, a weight ratio of the recrystallization solvent to the anti-solvent is in the range of 1.0 to 2.2, e.g., in the range of 1.0 to 2.0, or in the range of 1.0 to 1.8. In certain embodiments, a weight ratio of the recrystallization solvent to the anti-solvent is in the range of 1.4 to 2.2, e.g., in the range of 1.4 to 2.0, or in the range of 1.4 to 1.8.

[0133] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, at least 50 wt% of the compound of formula (I) crystallizes in crystallineform, based on the initial amount of the dissolved compound of formula (I). In certain embodiments, at least 55 wt%, e.g., at least 60 wt%, or at least 65 wt%, or at least 70 wt%, or at least 75 wt% of the compound of formula (I) crystallizes in crystalline form, based on the initial amount of the dissolved compound of formula (I). In certain embodiments, 50 to 90 wt%, e.g., 55 to 90 wt%, or 60 to 90 wt%, or 65 to 90 wt%, or 70 to 90 wt%, or 75 to 90 wt% of the compound of formula (I) crystallizes in crystalline form, based on the initial amount of the dissolved compound of formula (I).

[0134] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the process further comprises agitation of the recrystallization slurry. For example, in certain embodiments, the agitation of the recrystallization occurs in a wet milling slurry. In certain embodiments, the agitation of the recrystallization slurry is performed with a wet-milling frequency, at a wet-milling temperature, for a wet-milling time.

[0135] In certain embodiments, the wet-milling frequency is in the range of 10,000 to 30,000 rpm, e.g., in the range of 10,000 to 25,000 rpm, or in the range of 10,000 to 20,000 rpm. In certain embodiments, the wet-milling frequency is in the range of 12,000 to 30,000 rpm, e.g., in the range of 12,000 to 25,000 rpm, or in the range of 20,000 rpm. In certain embodiments, the wet-milling frequency is in the range of 15,000 to 30,000 rpm, e.g., in the range of 15,000 to 25,000 rpm, or in the range of 15,000 to 20,000 rpm.

[0136] In certain embodiments, the wet-milling temperature is in the range of 20 to 80 °C, e.g., in the range of 20 to 75 °C, or in the range of 20 to 70 °C, or in the range of 20 to 65 °C. In certain embodiments, the wet-milling temperature is in the range of 20 to 80 °C, e.g., in the range of 30 to 75 °C, or in the range of 30 to 70 °C, or in the range of 30 to 65 °C. In certain embodiments, the wet-milling temperature is in the range of 40 to 80 °C, e.g., in the range of 40 to 75 °C, or in the range of 40 to 70 °C, or in the range of 40 to 65 °C.

[0137] In certain embodiments, the wet-milling time is in the range of 3 to 14 hours, e.g., in the range of 3 to 12 hours, or in the range of 3 to 10 hours. The person of ordinary skill in the art will appreciate that a particular number of turnovers of the recrystallization slurry (i.e., the number of time the recrystallization slurry is circulated through the wet mill) can lead to a desired particle size distribution of the crystallized compound of formula (I). Accordingly, in certain embodiments, the wet-milling time is an amount of time sufficient for at least 5 turnovers, e.g., at least 10 turnovers, or at least 15 turnovers of the recrystallization slurry.

[0138] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the process further comprises:adding seed crystals to the recrystallization slurry,wherein the seed crystals are the chiral bicyclic ketone compound of formula (I) in the crystalline form.

[0139] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the seed crystals are added in an amount in the range of 1 to 10 wt%, e.g., in the range of 1 to 8 wt%, or in the range of 1 to 6 wt%, relative to the initial amount of the compound of formula (1-1). In certain embodiments, the seed crystals are added in an amount in the range of 2 to 10 wt%, e.g., in the range of 2 to 8 wt%, or in the range of 2 to 6 wt%, relative to the initial amount of the compound of formula (1-1).

[0140] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits one or more features selected from:a Amax absorption in the range of 700 to 720 cm'1when subjected to Raman spectroscopy;peaks of at least about 7.5° 20, about 8.2° 20, about 18.2° 20, about 20.0° 20, about 24.5° 20, and about 25.7° 20 when subjected to x-ray powder diffraction spectroscopy;the loss of no more than 0.5 wt% when subjected to thermal gravimetric analysis up to 150 °C; andan endothermic peak in the range of 159 to 162 °C when subjected to differential scanning calorimetry.In certain embodiments, the crystalline form of the compound of formula (1-1) exhibits one of the above features. In certain embodiments, crystalline form of the compound of formula (I-1) exhibits at least one of the above features (e.g., two, three, or four of the above features). In certain embodiments, crystalline form of the compound of formula (I) exhibits all of the above features.

[0141] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits a Amax absorption in the range of 700 to 720 cm'1when subjected to Raman spectroscopy. In certain embodiments, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits a Raman spectrum corresponding to the Raman spectrum shown in FIG. 1.

[0142] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits peaks of at least about 7.5° 20, about 8.2° 20, about 18.2° 20, about 20.0° 20,about 24.5° 20, and about 25.7° 20 when subjected to x-ray powder diffraction (XRPD) spectroscopy. In certain embodiments, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits a XRPD spectrum corresponding to the XRPD spectrum shown in FIG. 2.

[0143] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits loss of no more than 0.5 wt% when subjected to thermal gravimetric analysis up to 150 °C.

[0144] In certain embodiments of the process for providing the compound of formula (1-1) in a crystalline form, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits an endothermic peak in the range of 159 to 162 °C when subjected to differential scanning calorimetry (DSC). In certain embodiments, the crystalline form of the compound of formula (1-1) is characterized in that it exhibits a DSC graph corresponding to the DSC graph shown in FIG. 4.

[0145] In another aspect, the disclosure provides for a compound of formula (1-1) provided from the processes disclosed herein. In another aspect, the disclosure provides for a compound of formula (1-1) in a crystalline form provided from the processes disclosed herein.

[0146] In another aspect, the disclosure provides for a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern with peaks of at least about 7.8° 20, about 8.8° 20, about 15.2° 20, about 17.5° 20, about 20.5° 20, about 23° 20, and about 25.7° 20 (i.e., a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1 ,2-b][1 ,2,4]triazol-2-yl)methanone of crystalline Form A). For example, in certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a X-ray powder diffraction pattern as shown in “Form A” of Figure 2.

[0147] In certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a Raman infrared spectrum with a Amax absorption in the range of 700 to 720 cm'1. For example, in certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a Raman infrared spectrum as shown in “Form A” of Figure 2.

[0148] In certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone exhibits a loss of no morethan about 0.5 wt% when subjected to thermogravimetric analysis. For example, in certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone exhibits a loss of in the range of 0.4 wt% to 0.5 wt% when subjected to thermogravimetric analysis.

[0149] In certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a differential scanning calorimetry endothermic peak in the range of about 159 °C to 162 °C. In certain embodiments, the crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone does not exhibit a differential scanning calorimetry endothermic peak in the range of 118 °C to 126 °C. For example, in certain embodiments, the crystalline Form A of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a differential scanning calorimetry curve as shown in Figure 4.

[0150] In another aspect, the disclosure provides for a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yljmethanone having an X-ray powder diffraction pattern with peaks of at least about 11.2° 20, about 13.8° 20, about 14.9° 20, about 17.6 ° 20, about 19.7 ° 20, about 20.3 ° 20, about 22.6 ° 20, and about 24.4° 20 (i.e. , a crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone of crystalline Form B). For example, in certain embodiments, the crystalline Form B of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a X-ray powder diffraction pattern as shown in “Form B” of Figure 3.

[0151] In certain embodiments, the crystalline Form B of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a Raman infrared spectrum with a Amax absorption in the range of 730 to 740 cm-1. For example, in certain embodiments, the crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a Raman infrared spectrum as shown in “Form B” of Figure 3.

[0152] In certain embodiments, the crystalline Form B of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone exhibits a loss of no more than about 0.6 wt% when subjected to thermogravimetric analysis. For example, in certain embodiments, the crystalline Form B of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone exhibits a loss in the range of 0.5 wt% to 0.6 wt% when subjected to thermogravimetric analysis.

[0153] In certain embodiments, the crystalline Form B of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a first differential scanning calorimetry endothermic peak in the range of about 118 °C to 126 °C and a second differential scanning calorimetry endothermic peak in the range of 159 °C to 162 °C. For example, in certain embodiments, the crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone has a differential scanning calorimetry curve as shown in Figure 5.EXAMPLES

[0154] The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention. These examples serve to provide guidance to a skilled artisan to prepare and use the compounds, compositions and methods of the invention. While particular embodiments of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the inventions.

[0155] The chemical reactions in the examples described can be readily adapted to prepare a number of other compounds of the invention, and alternative methods for preparing the compounds of this invention are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention can be successfully performed by modifications apparent to those skilled in the art, for example, by appropriately protecting interfering group, by utilizing other suitable reagents known in the art, for example, by appropriately protecting interfering groups by utilizing other suitable reagents known in the art other than those described, and / or by making routine modifications of reaction conditions.

[0156] In the examples below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Commercially available reagents were purchased from suppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge and were used without further purification unless otherwise indicated. The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and / or heat dried.1H NMR spectra were obtained in deuterated CDCh, de-DMSO, CH3OD or de-acetone solvent solutions (reported in ppm) using or trimethylsilane (TMS) or residual non-deuterated solvent peaks as the reference standard. When peak multiplicities are reported, the following abbreviates are used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet, br(broadened)), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are reported in Hz (Hertz).Example 1: Preparation of tert-butyl ((3R,5S)-3-hydroxy-2-oxo-5-phenylpyrrolidin-1-yljcarbamate (Compound 1) / . N(CH3)4CI NaHB(AcO)3AcOH, CH2CI2 / / . EtOH62% yield Compound 1

[0157] To a glass reactor is charged dichloromethane (156.4 kg, 13.3 wt. / wt., 10 vol.), N(CH3)4CI (7.7 kg, 2.0 eq.) and NaBH(OAc)3 (9.7 kg, 45.6 mol, 1.3 eq.). The temperature of the reactor content is cooled to -10 to 0°C. To the mixture is added tert-butyl (R,Z)-2-(4-ethoxy-3-hydroxy-4-oxo-1-phenylbutylidene)hydrazine-1-carboxylate (11.8 kg, 35.1 mol, 1.0 eq.) at -10 to 0°C. The contents are agitated for 2-3 h after cycled from vacuum to nitrogen three times. HOAc (93.0 kg, 7.88 w / w, 7.5 vol.) is charged dropwise to the contents. After the addition, the mixture is agitated for 16-20 h at -10 to 0°C. To the mixture is then charged EtOH (18.6 kg, 1.58 wt. / wt., 2 vol.). The reaction is agitated for 1h to 2 h at -10 to 0°C and then heated to 20-30 ° and further agitated for 18 to 20 h. The reaction mixture is quenched by H2O (59.0 kg, 5 w / w, 2 vol.) and then extracted twice by dichloromethane (78.2 kg, 6.63 w / w, 5 vol.). The combined organic phases are washed four times with 10 wt% Na2COs (each with 59.0 kg, 5.0 w / w, 5 vol.) followed by 3% aq. Na2SO4 (each with 59.0 kg, 5.15 w / w, 5 vol.) wash twice. The washed organic phase is concentrated to 1.0-1.5 v and swapped twice with EtOAc (each with 21.2 kg, 1.80 w / w, 2 vol.) to 1.0-1.5 v below 50 °C. EtOAc (21.2 kg, 1.80 w / w, 2 vol.) is charged to concentrate the residue and heated to 55 to 65 °C and toluene (154.3 kg, 13.086 w / w, 15 vol.) is charged dropwise to the mixture. The temperature of the contents is adjusted to -5 to 5 °C over 4-5 h and then further agitated for 16 h at -5 to 5 °C. The contents are centrifuged, and the cake is washed with toluene (10.3 kg, 0.87 w / w, 1 vol.). The cake is dried at 45 to 50 °C for 16-20 h. A white solid of compound 1 (6.36 kg, 0.54 w / w, 21.8 mol, 62.0% yield (uncorrected), 99.9% achiral purity and 99.5% chiral purity) is obtained. HRMS (m / z) calculated for C15H20N2O4 [M+Na]+315.1315, found 315.1345.1H NMR (d-DMSO, 400 MHz): bH9.20 (s, 1H), 7.30 (m, J = 7.2 Hz, 5H), 5.80 (d, J = 5.2 Hz, 1H), 4.82 (dd, J = 4.4, 4.8 Hz, 1H), 4.30 (q, J = 6.4, 6.8 Hz, 1H), 2.21 (m, J = 1.2 Hz, 2H), 1.35(s, J = 7.92 Hz, 9H).13C NMR (d-DMSO, 100 MHz): bc172.9, 154.4, 140.9, 129.0, 128.1, 127.2, 80.2, 66.1, 60.5, 37.3, 28.4.Example 2: Preparation of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone (Compound 7)OH HCI, n-PrOH Et3N, Et3N«3HF PhCF^ THF, 60 °C 10-15 C 1 79% 2 95% 3 Step 1 Step 2NaOH, H2O AcOH 10-15 c, 1 h EtOH 90 °C 80% 4 Step 3 Step 4Step 5 Step 6Synthesis of Tert-butyl ((3R)-3-hydroxy-2-oxo-5-phenylpyrrolidin-1-yl)carbamate (Compound 2)

[0158] To a reactor under nitrogen is charged tert-butyl ((3R,5S)-3-hydroxy-2-oxo-5-phenylpyrrolidin-1-yl)carbamate (388.6 g, 1.31 mol, 1.00 equiv) and 5-chloropyridine-2-sulfonyl fluoride (466.0 g, 2.35 mol, 1.80 equiv), followed by THF (3.11 L, 8.00 L / kg). Et3N (797.0 g, 7.84 mol, 6.00 equiv) and Et3N 3HF (430.0 g, 2.61 mol, 2.00 equiv) are added dropwise at 20-30 °C. The mixture is heated to 60 °C and stirred for 18 h.

[0159] The reaction mixture is cooled to 25 °C, and then MeOH (0.31 L) is added. The mixture is stirred for 1 h. The solution is concentrated to 4-5 L / kg. Then toluene (1.94 L) is added and concentrated to 5 L / kg. Toluene (1.94 L) is added.

[0160] Water is added (1.94 L) and contents of the reactor are agitated for 15 min. The layers are separated and the organic layer containing 5-chloropyridine-2-sulfonyl fluoride was washed sequentially with 10 wt% aqueous citric acid (2 x 1.94 L, 5 L / kg), 5 wt%aqueous sodium bicarbonate (1.94 L, 5 L / kg), and 15 wt% aqueous NaCI (1.94 L, 5 L / kg). Toluene (2 mL / g) was added before organic layer was concentrated to 9-10 mL / g. The reaction was sampled for I PC (Target (KF) < 0.5 wt%, Result: 0.05 wt%, Met)

[0161] Contents of the reactor containing tert-butyl ((3S,5S)-3-fluoro-2-oxo-5-phenylpyrrolidin-1-yl)carbamate are transferred to a carboy, and the reactor is washed before the contents of the carboy are added back to the reactor. Re-circulative charcoal treatment is performed using cartridge containing Graver C-941 (75.0 g, 12 wt%) for 2 h at room temperature. The cartridge is washed with 2 L / kg of Toluene and the wash layer was combined with the contents of the reactor.

[0162] The contents of the reactor are concentrated to 4 L / kg, the temperature is adjusted to 35 °C and EtOH (77 mL) was added. To the solution was charged heptane (1.55 L) over 30 min. The temperature was adjusted to 30 °C, then tert-butyl ((3S,5S)-3-fluoro-2-oxo-5-phenylpyrrolidin-1-yl)carbamate seeds (0.100 g, 2 wt%) as a slurry in heptane (30.00 mL, 0.200 mL / g) are added. After aging for 1.5 h, heptane (3.2 L) is added to the resultant suspension over 3 h. The slurry is cooled to 10 °C over 4 h, and aged at 10 °C for 4 h. Three heating and cooling cycles are performed: the temperature is brought to 45 °C over 30 min, aged for 1 h, then cooled down to 10 °C over 2h. The resulting slurry is aged for 2 h.

[0163] The solid is collected by filtration, washed with heptane, and dried under N2 and vacuum at 23 °C for 24 h to give Compound 2 (288.5 g, 75% corrected yield) as an off white solid.

[0164] 1H NMR (400 MHz, d6-DMSO) 59.40 (s, 1H), 7.41-7.32 (m, 5 H), 5.37 (dt, J = 52.0, 8.0 Hz, 1H), 4.72-4.62 (d, J = 41.9 Hz, 1H), 3.33-3.02 (dd, J = 13.3, 7.0 Hz, 1H), 2.13-1.92 (m, 1H), 1.35 (s, 9 H).13C NMR (101 MHz, CDCI3) 6 169.0 (d, J= 17.8 Hz), 153.8 (s), 138.1 (s), 129.1 (s), 128.9 (s), 127.3 (s), 86.1 (d, J= 188.2 Hz), 82.3 (s), 59.6 (s), 34.9 (d, J= 19.2 Hz), 28.0 (s). HRMS calculated for C15H19FN2O3 Na [M + Na]+317.1272, found m / z 317.1273 (operation mode: ESI Positive Ion Mode).Synthesis of (3S,5S)-1-amino-3-fluoro-5-phenylpyrrolidin-2-one HCI salt (Compound 3)

[0165] To a flask (2 L) are charged with toluene (177 mL, 3 vol.) and tert-butyl ((3S,5S)-3-fluoro-2-oxo-5-phenylpyrrolidin-1-yl)carbamate (59 g, 0.2 mol, 1.0 equiv.) at 0-5 °C under N2 atmosphere. A solution of HCI I n-propanol (531 mL, 6 M, 9 vol., 15.9 equiv.) is added dropwise at 0-10 °C over 0.5 h. The reaction mixture is stirred at 10-25 °C for 2 h. The suspension is filtered. The cake is washed with toluene (100 mL). The cake is dried under vacuum (2 mm Hg) at 40 °C for 4 h to provide 42 g of Compound 3 as a white solid with98.3% HPLC purity and 98.2 wt% assay by qNMR and 99.6 A% chiral HPLC purity in 90% isolated yield.

[0166] 1H NMR (400 MHz, MeOD) 57.66 - 7.36 (m, 5H), 5.51 - 5.24 (m, 1 H), 4.93 (td, J = 6.3, 3.3 Hz, 1 H), 3.27 - 3.08 (m, 1 H), 2.18 (dddd, J = 27.5, 14.3, 6.3, 2.0 Hz, 1 H).13C NMR (101 MHz, MeOD) 5 167.2 (d, J = 20.6 Hz), 135.9 (s), 127.6 (s), 127.5 (s), 125.4 (s), 85.5 (d, J = 183.0 Hz), 59.7 (s), 32.9 (d, J = 19.6 Hz). HRMS The theoretical calculated for C10H12ON2F (M (freebase) + H): 195.0928, found m / z 195.0929 (operation mode: ESI positive Ion Mode).Synthesis of (3S,5S)-1-amino-3-fluoro-5-phenylpyrrolidin-2-one (Compound 4)

[0167] To a flask (250 mL) are charged with (3S,5S)-1-amino-3-fluoro-5-phenylpyrrolidin-2-one HCI salt (42 g, 182 mmol, 1.0 eq.) and water (63 mL, 1.5 vol.) at 0-5 °C under N2 atmosphere. Aqueous NaOH (7.4 g, 21 mL water, 0.5 vol.) is added dropwise at 0-10 °C over 0.5 h to pH=8. The mixture (slurry) is stirred at 15-25 °C for 0.5 h. The mixture (slurry) is filtered.

[0168] The cake is washed with water (40 mL). The cake is collected and dried under vacuum (2 mm Hg) at 40 °C to provide 32 g of Compound 4 with 96.7% HPLC purity and 94.3 wt% assay by qNMR and 99.9 A% chiral HPLC purity in 90% isolated yield.

[0169] 1H NMR (400 MHz, d6-DMSO) 57.39 - 7.26 (m, 5 H), 5.32-5.24 (ddd, J = 53.4, 8.2, 5.6 Hz, 1 H), 4.58-4.53 (dd, J = 12.4, 5.9 Hz, 3 H), 2.98-2.87 (m, 1 H), 1.85-1.72 (ddt, J = 28.6, 13.8, 5.8 Hz, 1 H).13C NMR (101 MHz, d6-DMSO) 5167.4 (d, J = 19.8 Hz), 141.0 (s), 129.1 (s), 128.2 (s), 127.2 (s), 88.1 (d, J = 180.2 Hz), 61.2 (d, J = 1.8 Hz), 34.9 (d, J = 19.0 Hz). HRMS The theoretical calculated for C10H12ON2F (M + H): 195.0928, found m / z 195.0929 (operation mode: ESI Positive Ion Mode).Synthesis of ethyl (5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxylate (Compound 5)

[0170] To a 25 mL three-necked flask is refilled with N2for three times. The flask is charged with (3S,5S)-1-amino-3-fluoro-5-phenylpyrrolidin-2-one (10 g, 51.5 mmol, 1.0 equiv.), EtOH (100 mL, 10 vol.), ethyl 2-ethoxy-2-iminoacetate (18.8 g, 128.7 mmol, 2.5 equiv.) and AcOH (9.3 g, 154.5 mmol, 3.0 equiv.). The mixture is heated to reflux and stirred for 5 h. The mixture is filtered at 60 °C and the cake is washed with EtOH (20 mL x 2, 2 vol.). The filtrate is concentrated under vacuum at 40 °C to give 22.6 g of crude 11 with 56.8% assay purity in 90% in-process yield. / PrOH (6.5 vol. 147 mL) is added and the resulting mixture is heated for the dissolution. The solution is cooled to 25 °C over a period of 1 h. The mixture is stirred for 16 h at 20-25 °C. The mixture is filtered and rinsed with / PrOH (10 mL). The cake is driedunder vacuum (5 mm Hg) at 40 °C to provide 9.6 g of Compound 5 with 98.8% HPLC purity and 99.4 wt% assay by qNMR in 73% isolated yield (corrected).

[0171] 1H NMR (400 MHz, d6-DMSO) 67.48 - 7.35 (m, 3 H), 7.29 - 7.21 (m, 2 H), 6.23 (ddd, J = 56.5, 7.2, 1.8 Hz, 1 H), 5.75 - 5.66 (m, 1 H), 4.32 (qd, J = 7.1 , 3.0 Hz, 2 H), 3.87 -3.64 (m, 1 H), 2.83-2.62 (m, 1 H), 1.29 (t, J= 7.1 Hz, 3 H).13C NMR (101 MHz, CDCI3) 6 159.8 (s), 158.4 (s), 157.7 (d, J= 22.7 Hz), 136.1 (s), 128.2 (s), 128.2 (s), 125.7 (s), 81.2 (d, J= 184.6 Hz), 61.1 (s), 60.1 (s), 42.4 (d, J= 23.1 Hz), 13.2 (s). H RMS The theoretical calculated for C14H15O2N3F (M + H): 276.1143, found m / z 276.1142 (operation mode: ESI Negative Ion Mode).Synthesis of [(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-morpholino-methanone (Compound 6)

[0172] In a 1000 mL triple-jacketed reactor, under nitrogen atmosphere, at Jacket Temperature (Tj) 20°C is charged ethyl (5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxylate (50.0 g, 1.0 eq.) followed by morpholine (156.6 g, 10.0 eq.). Light suspension formed. Suspension is cooled to internal temperature (IT) 0 °C. With a syringe pump in 10 minutes is added lithium methoxide in methanol (27.03 g, 0.400 eq, 10 wt%). The syringe and transfer pipe are washed with additional methanol (5 g).Reaction mixture is further stirred for 15 minutes. When by I PC is confirmed < 0.5 area% starting material, to the reaction mixture is added acetic acid in water (750 g, 10 w / w%) over 3-hour period. The reaction mixture is stirred overnight at 0 °C and solids are filtered off via paper filter. The reactor, transfer tubes and filter cake are washed with additional water (6 x 100 g, 6 portions). The pH of the last water wash is neutral (pH = 7). The obtained solids are dried overnight at Tj = 50 °C (<10 mbar) to give the final product 52.7 g (Yield: 93.5 %) Compound 6 with 99.9a% HPLC purity and > 99.95:0.05 dr.

[0173] 1H NMR (400 MHz, d6-DMSO) 57.45 - 7.35 (m, 3H), 7.27 - 7.20 (m, 2H), 6.17 (ddd, J = 56.4, 7.01.9 Hz, 1 H), 5.67 (ddd, J = 8.4, 6.9, 3.0 Hz, 1 H), 3.80-3.67 (m, 1 H), 3.68 - 3.52 (m, 8H), 2.74-2.63 (m, 1H).13C NMR (100 MHz, d6-DMSO) 5162.64, 160.07, 158.56, 158.34, 138.98, 129.51, 129.06, 127.07, 84.55, 82.78, 66.80, 66.47, 60.29, 47.44, 43.77, 43.56, 42.62. LC / MS: C16H17FN4O2 [M+H]+317.2 m / z, (operation mode: ESI Positive Ion Mode).Synthesis of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone (Compound 7)

[0174] Batch Process:

[0175] In 300 mL tri pie- Jacketed reactor (R1), under nitrogen atmosphere, at Jacket temperature (Tj) 20°C of [(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-morpholino-methanone (10.0 g, 1.0 eq.) is charged followed by THF (88 g, 10V) to form a light suspension. The suspension is cooled to internal temperature (IT) 10°C. With the syringe pump during 60 minutes cyclopropyl magnesium bromide (102.09 g, 1.6 eq. 0.47 M in THF) is added to the light suspension. The syringe and transfer lines are washed with additional THF (17.6 g). The reaction mixture is stirred for a further 60 minutes, then warmed to IT 20 °C over 60 minutes and stirred further 120 minutes at IT 20 °C. In another triple-jacketed reactor (R2) is prepared acetic acid (50 mL, 10 w / w%, 2.82 equiv). When IPC shows < 2 area% of [(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-morpholino-methanone the reaction mixture from R1 is transferred then to reactor R2 over 30-minute period. The reactor R1 and transfer tubes are further washed with THF (17.6 g). The biphasic mixture R2 is further stirred for 5 minutes and then allowed to settle for 5 minutes. The aqueous phase is separated from the organic phase.

[0176] Flow Process:

[0177] Feed Solution preparation: [(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1 ,2-b][1,2,4]triazol-2-yl]-morpholino-methanone (12.5 g, 1.0 eq.) is dissolved in THF (143 g, 13V) to give a Feed A solution. 10 wt% Acetic acid is prepared from glacial acetic acid (100 g) and water (900 g).

[0178] Flow Process: Feed A (1.26x mL / min) is dosed together with c-PrMgBr (0.99x mL / min, 1.60 equiv, 0.47 M in THF) in a flow reactor 1. The temperature in the flow reactor 1 is 10 -25 °C. When IPC shows < 2 area% [(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-morpholino-methanone the reaction mixture is transferred to the flow reactor 2 where acetic acid (0.51x mL / min, 3.0 equiv) is added. The aqueous phase is separated from the organic phase.

[0179] Flow Reactor: plug flow reactor and / or continuous-stirred tank reactor.

[0180] Crystallization Procedure:

[0181] The organic phase is distilled at JT 40 °C (300 mbar) to the end volume of ca. 100 mL. Light suspension formed. Within 90 minutes to the light suspension water (200 g) is added. The light suspension is cooled to 20 °C and stirred overnight. The suspension is filtered over glass nudge with paper filter. The reactor, transfer lines and solids are washed with water (overall 100 g in 3 portions). The solids are dried overnight < 10 mbar (Tj 50 °C) to give Compound 77.55 g (89.8% yield) with 99.7a% HPLC purity and > 99.95:0.05 dr.

[0182] 1H NMR (400 MHz, d6-DMSO) 67.48 - 7.35 (m, 3H), 7.33 - 7.21 (m, 2H), 6.24 (ddd, J = 56.4, 7.22.0 Hz, 1H), 5.73 (ddd, J = 8.5, 6.5, 3.1 Hz, 1H), 3.80-3.67 (m, 1H), 3.04-2.95 (m, 1H), 2.74-2.63 (m, 1H), 1.14-1.09 (m, 4H),13C NMR (100 MHz, d6-DMSO) 5 192.7, 165.6, 159.1, 138.3, 129.1, 128.7, 126.7, 83.2, 60.0, 43.0, 17.9, 11.9, 11.8. LC / MS:C15H15FN3O [M+H]+272.1 m / z (operation mode: ESI Positive Ion Mode).Example 3: Crystallization of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone (Form A)

[0183] 1 L, 5 L, and 10 L glass bottles, 10 L and 30 L glass reactors are equipped with temperature controlled jacket, impeller, and reflux condenser, Sartorius polish filters (pore size: 20 pm, part#: 5058320P1-SS), Watson Marlow 600 series peristaltic pump, IKA magic LAB wet mill in DR mode (2G4M6F) fitted with 1 ” tubing, and a 20 L GL Filter Dryer are used.

[0184] To a 10 L reactor is charged Compound 7 (1.12 kg, 4.14 mol, 1.0 equiv) and acetone (5.00 mL / g, 4.44 kg, 5.61 L) and the mixture is heated to 45 °C to obtain a clear solution. The solution is polish filtered into a 30 L reactor and rinsed with acetone (2 x 0.25 mL / g, 2 x 0.222 kg, 2 x 0.281 L). To the solution at 45 °C is then added polish filtered water (1.86 mL / g, 2.09 kg) over 30 min, and the mixture seeded with a slurry of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone -Form A (44.9 g, 0.04 equiv) in polish filtered acetone / water (2:3, v / v, 0.30 mL / g, 0.309 kg). The seed suspension bottle is then rinsed with polish filtered acetone / water (2:3, v / v, 0.10 mL / g, 0.103 kg) and the bottle contents transferred to the reactor. The resulting suspension is recirculated through an IKA magic LAB wet mill (DR, 2G4M6F, 18,000 rpm) for 5 turnovers, and aged for 16 h at 45 °C. To the slurry is added polish filtered water (2.88 mL / g, 3.23 kg) slowly over 5 h, followed by a second portion of polish filtered water (2.88 mL / g, 3.23 kg) slowly over 2 h. The mixture is then aged for 3 h at 45 °C, cooled to 30 °C over 5 h, aged at 30 °C for 7 h, and recirculated through an IKA magic LAB wet mill (DR, 2G4M6F, 5,000-20,000 rpm) for 90 turnovers. The solids are collected by filtration, the cake is washed with polish filtered acetone / water (2:3, v / v, 5.00 mL / g, 5.14 kg) and dried in the filter dryer at 50 °C for 17 h to give 0.867 kg (79% yield) as a pale orange-yellow solid.Example 4: Crystallization of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone (Form B)

[0185] Form B was obtained in EtOAc / MTBE system. Specifically, saturated EtOAc solution of Compound 7 was prepared. One volume of MTBE and 1% Form B seed was added to the EtOAc solution, followed by addition of another two volumes of MTBE. The suspensionwas then transferred to 5 °C. After stirring overnight, Form B was obtained. Form B sample showed 0.5% weight loss up to 150 °C. Two endothermic peaks at 119.5 °C and 159.9 °C (onset temperature) were observed and the sharp endothermic peak before decomposition was probably caused by melting (Figure 5). Almost no signal of EtOAc or MTBE was detected in the 1H NMR spectrum, indicating Form B is not a solvate.

[0186] Form A and Form B are enantiotropic with Form A being thermodynamically more stable than Form B when the temperature is higher than 5 °C, and Form B being thermodynamically more stable than Form A when the temperature is lower than 0 °C. Although both Form A and B are anhydrous and non-hygroscopic, considering the higher thermodynamic stability of Form A when the temperature is higher than 5 °C.Example 5: Additional synthesis of ethyl (5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole-2-carboxylate (Compound 5)o

[0187] To a 500 mL reactor under nitrogen is charged anhydrous n-PrOH (106 g, 132 mL, 4.4 mL / g). The internal temperature is adjusted to -10±10 °C. To the reactor is charged acetyl chloride (29.9 g, 380, mmol, 4.00 equiv) dropwise over 1 h while maintaining an internal temperature of 0±5 °C. To a separate 250 mL round bottom flask is charged compound 2 (30.0 g, 101 mmol, 1.00 equiv) and toluene (157 g, 180.0 mL, 6.0 mL / g) at 25 °C. The solution of compound 2 is agitated until a dark purple homogeneous solution is obtained. After full dissolution, the solution of compound 2 is added to the 500 mL reactor dropwise while maintaining an internal temperature of 0±10 °C. After addition the internal temperature is adjusted to 25 °C over 30 min and the reaction is agitated for 12 h. During this time the pink-purple reaction solution turns into a light pink slurry.

[0188] The reaction slurry is transferred to a Whatman® ZapCap® filter and the filtrate is collected in a 2 L glass Pyrex bottle. After the 500 mL reactor is rinsed with toluene (52.3 g, 60.0 mL, 2.0 mL / g) and the rinse is transferred to the filter. The solid cake in the filter is rinsed with toluene (52.3 g, 60.0 mL, 2.0 mL / g). Crude compound 3 is dried under N2sweep at 25 °C jacket temperature for a minimum of 2 h, and dried in a vacuum oven at 40±5 °Cjacket temperature for 24 h. Crude compound 3 was isolated in 99.1% corrected yield (90.1 wt%; 98.79 A% HPLC).1. NaOH (4M, 1.00 1.1 equiv),pH 7.5 potassium phosphateF buffer (0.2M, 5 mL / g) F°VXMeCN(5 mL / 9)’ 10-15 °C, 1 hHCI* T \ _ ] \N 7 N^ / H2N' \ 2. EtOH / heptane (3 mL / g : 16 H2N'™ mL / g) Ph360^25°C489%

[0189] To a 100 mL EasyMax reactor under N2 atmosphere at 25 °C is charged compound 3 (5.00 g, 21.68 mmol, 1.00 equiv), acetonitrile (6.0 mL / g, 23.5 g, 30 mL) and 0.2 M potassium phosphate buffer at pH 7.5 (25 mL, 5 mL / g, 5.0 mmol, 0.23 equiv). A yellow homogeneous solution is observed. To the reactor is charged an aqueous solution of 2.0 M NaOH (12.1 g, 22.8 mmol, 1.05 equiv) to adjust the pH. Bilayer formation is observed in the reactor after base addition.

[0190] The reaction is agitated for 1 h. After the layers are separated and the bottom aqueous layer is back-extracted 2x with MeCN (19.6 g, 25 mL, 5 mL / g). The organic layers containing compound 4 are combined and the final aqueous layer is discarded. The combined organic layers are concentrated to dryness and then dissolved in EtOH (95 g, 120 mL, 24 mL / g) at 60°C. The solution of compound 4 in EtOH is polish filtered and the reaction vessel and filter are rinsed with EtOH (8 g, 10 mL, 2 mL / g). The final solution is then concentrated to approximately ~3 mL / g under reduced pressure at 60 °C jacket. The solution is then slowly cooled to 25 °C over 1 h. Heptane (54.7 g, 80.0 mL, 16 mL / g) is charged over 1 h to the reaction vessel. The resulting slurry is then aged for 12 h at 25 °C.

[0191] The reaction slurry is filtered. After the reactor vessel is rinsed with heptane (10.3 g.15 mL, 3.0 mL / g), the rinse is transferred to the filter. The solid cake in the filter is rinsed with heptane (10.3 g, 15 mL, 3.0 mL / g). Crystallized 4 is dried under N2 sweep at 25 °C jacket temperature for a minimum of 2 h, and then dried in a vacuum oven at 40±5 °C jacket temperature for 24 h.AcOH (3 equiv.)EtOH (12V) 90 °C

[0192] To a 40 mL vial under nitrogen is charged compound 4 (1.00 g, 4.14 mmol, 1.00 equiv), EtOH (7.91 g, 10 mL, 10.0 vol), ethyl 2-ethoxy-2-iminoacetate (1.86 g, 1.73 mmol, 2.50 equiv), and AcOH (930 mg, 883 pL, 15.44 mmol, 3.00 equiv) giving a suspension. The internal temperature is adjusted to 80±10 °C and the reaction is agitated for 18 h. During this time, the reaction clarifies to bright yellow solution before becoming a suspension again.

[0193] The internal temperature of the reaction is adjusted to 60±5 °C over 30 min. Then crude reaction mixture is polish filtered at 60±5 °C using a fritted funnel under reduced pressure. The solids are discarded and the mother liquor containing 5 was taken into isolation A or B below.

[0194] Isolation A: The solution containing 5 in EtOH (~12 mL / g) is concentrated to ~6 mL / g under reduced pressure at 60°C. Water (12 g, 12mL / g) is charged to the vial over 1h at 60±5 °C. Then the solution is cooled to 5±5 °C over 1h. The resulting slurry is agitated for 12 h at 5±5 °C. The slurry is transferred to a filter. The crystallization vial is rinsed with water (4 g, 4 mL / g) and then transferred to the filter. Crystallized 5 is dried under N2sweep at 25 °C jacket temperature for a minimum of 2 h, and then dried in a vacuum oven at 40±5 °C jacket temperature for 24 h, and isolated in 82% corrected yield (94.1 wt %; 98.21 A% HPLC).

[0195] Isolation B: The solution containing 5 in EtOH (~12 mL / g) is solvent swapped to IPA (approx. ~6.5 mL / g) under reduced pressure at 50±5°C. The solution is cooled to 25±5°C over 1h. The resulting slurry is agitated for 12 h at 25±5 °C. After aging, the resulting slurry is cooled to 15±5 °C and aged for 40 min. The slurry is transferred to a filter. The crystallization vial is rinsed with / -PrOH (393 mg, 0.5 mL / g) and then transferred to the filter. Crystallized 5 is dried under N2sweep at 25 °C jacket temperature for a minimum of 2 h, and then dried in a vacuum oven at 40±5 °C jacket temperature for 24 h, and isolated in 74.0% corrected yield (96.3 wt %; 99.01 A% HPLC).

[0196] In certain examples, chiral column retention times (min) are provided for certain stereoisomers. Unless otherwise specified, the stereochemistry shown in each structure represents relative configuration of a single stereoisomer, and absolute configuration ( / .e., “R” and / or “S”) is arbitrarily assigned.

[0197] All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, international and non-patent publications referred to in this specification are incorporated herein by reference in their entireties.

[0198] Although the foregoing embodiments of the present invention have been described in some detail to facilitate understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims. Accordingly, the described embodiments are to be considered as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims.

Claims

WE CLAIM:Claim 1. A process for the preparation of a chiral bicyclic ketone compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom and R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, Ci-Ce alkyl-N(RN)2, hydroxyl, hydroxymethyl, cyano, cyanomethyl, cyanoethyl, C(O)Ci-Ce alkyl, phenyl, benzyl, CH2-(C3-Ce cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl);each RNis independently selected from the group consisting of H, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, and Ci-Ce haloalkyl; or two RNmay together with the adjacent N form a 4-6 membered ring;R2is selected from the group consisting of H, Ci-Ce alkyl, Ci-Ce haloalkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkoxy, Ci-Ce thioalkyl, phenyl, benzyl, CH2- (C3-C6 cycloalkyl), CH2CH2-(C3-Ce cycloalkyl), CH2-(4 to 6 membered heterocyclyl), CH2CH2-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); wherein when a phenyl ring is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, and cyano;R3is selected from the group consisting of D, halogen, OH, CN, C1-C4 alkyl, Ci- 04 haloalkyl, cyclopropyl, C1-C4 alkoxy and C1-C4 haloalkoxy; andn is 1, 2 or 3;the process comprising:(e) contacting a chiral bicyclic acyl compound of formula (VII)or a salt thereof, with an organometallic compound of formula (VIII):R1—M(VIII)to form the chiral bicyclic ketone compound of formula (I), or the pharmaceutically acceptable salt thereof;wherein:R11is -NR51R52or 5- to 6-membered heterocyclyl optionally subsituted with one or more R6groups, whereinR51is H, Ci-Ce alkyl optionally substituted with one or more R53groups, or Ci- Ce cycloalkyl optionally substituted with one or more R54groups, R52is Ci-Ce alkyl optionally substituted with one or more R55groups, or Ci-Ce alkoxy optionally substituted with one or more R56groups, wherein each R53and R54is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; andeach R55and R56is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy;each R6is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy;M is lithium, MgX1, orZnX2, whereinX1and X2are each halide or R1, or a mixture thereof.Claim 2. The process of claim 1, wherein contacting the chiral bicyclic acyl compound of formula (VII) or a salt thereof is in presence of tetrahydrofuran or diethyl ether.Claim 3. The process of claim 1 or claim 2, wherein M is MgX1and X1is bromine.Claim 4. The process of any of claims 1-3, further comprising:(d) contacting a chiral bicyclic triazole compound of formula (VI):or a salt thereof, with a compound R11-H or a salt thereof, in the presence of a basic additive, to form the chiral bicyclic acyl compound of formula (VII), or the salt thereof; wherein Pg1is H or a hydroxyl protecting group and may be the same or different on each occurrence.Claim 5. The process of any of claims 1-4, wherein R11is:Claim 6. The process of claim 4 or claim 5, wherein the basic additive is lithium methoxide.Claim 7. The process of any of claims 4-6, wherein step (d) is in presence of methanol.Claim 8. The process of any of claims 1-7, further comprising:(c) contacting a compound of chiral N-amino lactam formula (IV):For a salt thereof, with an imidate compound of formula (V) in the presence of a second acid additive:NHor a salt thereof, to form the chiral bicyclic triazole compound of formula (VI), or the salt thereof.Claim 9. The process of claim 8, wherein the second acid additive is acetic acid, and in presence of ethanol.Claim 10. The process of claim 8 or claim 9, wherein each Pg1is ethyl.Claim 11. The process of any of claims 1-10, further comprising:(b) contacting a compound of formula (III):For a salt thereof, with a first acid additive or a second organic base to form the compound of formula (IV), or the salt thereof;wherein Pg2is a nitrogen protecting group and may be the same or different on each occurrence.Claim 12. The process of claim 11 , wherein contacting a compound of formula (III) is carried out in toluene and the first acid additive is hydrochloric acid.Claim 13. The process of claim 11 or claim 12, wherein the first acid additive is provided as a solution in a solvent comprising an alcohol solvent.Claim 14. The process of claim 13, wherein the first acid additive is provided as a solution in n-propanol.Claim 15. The process of any of claims 1-14, the process further comprising:(a) contacting a compound of formula (II):OHor a salt thereof, with a halogenating agent to form the compound of formula (III), or the salt thereof.Claim 16. The process of claim 15, wherein the halogenating agent is:4-CI-C6H4SO2F, 4-CF3-C6H4SO2F, 4-NO2-C6H4SO2F, 4-CH3-C6H4SO2F, 2-NO2-C6H4SO2F, perfluorobutanesulfonyl fluoride, N-tosyl-4-chlorobenzenesulfonimidoyl fluoride, tetramethylfluoroformamidinium hexafluorophosphate, diethylaminosulfur trifluoride, bis(2-methoxyethyl)aminosulfur trifluoride, or (diethylamino)difluorosulfonium tetrafluoroborate.Claim 17. The process of claim 15, wherein the halogenating agent is 2-pyridinesulfonyl fluoride.Claim 18. The process of claim 15, wherein the halogenating agent is 5-chloro 2-pyridinesulfonyl fluoride.Claim 19. The process of any of claims 15-18, wherein contacting the compound of formula (II) in presence of tetrahydrofuran, diethyl ether, or toluene.Claim 20. The process of any of claims 15-19, wherein the contacting of the compound of formula (II), or the salt thereof with the halogenating agent is performed in the presence of a first organic base.Claim 21. The process of claim 20, wherein the first organic base is selected from triethylamine, N,N-diisopropylethylamine, 4-methylmorpholine, 1,8-diazabicyclo[5.4.0]undec-7-ene, 2-terf-butyl-1,1,3,3-tetramethylguanidine, and 7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene.Claim 22. The process of claim 20, wherein the first organic base is triethylamine or N,N-diisopropylethylamine.Claim 23. The process of claim 20, wherein the first organic base is triethylamine.Claim 24. The process of any one of claims 20-23, wherein step (a) is performed in the presence of a fluoride source additive.Claim 25. The process of claim 24, wherein the fluoride source additive is triethylamine trihydrofluoride, cesium fluoride, N,N-diisopropylethylamine trihydrofluoride, pyridine hydrofluoride, tetrabutylammonium difluorotriphenylsilicate, or tetrabutylammonium fluoride.Claim 26. The process of claim 25, wherein the fluoride source additive is triethylamine trihydrofluoride.Claim 27. The process of any one of claims 1 to 26, wherein the chiral bicyclic ketone compound of formula (I) is a compound selected from the group consisting of:F F F0 N. _ J0°RiJ y^ .z -^ KIR1y^n(I-2) (I-3)(1-1)F F F00 0z v KI yR M< N T-NV y]nfR1 N-NVfZ ^FfF(I-5)(I-4)(I-6)F0M T y}nCF3(I-7)or a pharmaceutically acceptable salt thereof, wherein:each R4is selected from the group consisting of F, Cl, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy and Ci-Ce haloalkoxy; andm is 0, 1, 2 or 3.Claim 28. The process of any one of claims 1 to 26, wherein the chiral bicyclic ketone compound of formula (I) is:For a pharmaceutically acceptable salt thereof.Claim 29. The process of any one of claims 1 to 28, wherein m is 0.Claim 30. The process of any one of claims 1 to 29, wherein R1is cyclopropyl.Claim 31. The process of any one of claims 1 to 30, wherein at least one step of the process is scalable to at least a kilogram scale.Claim 32. The process of any one of claims 1 to 31, the process further comprising:(f) dissolving an initial amount the chiral bicyclic ketone compound of formula (I) in a recrystallizing solvent to provide a recrystallization slurry;(g) adding portions of an anti-solvent to the recrystallization slurry until at least a portion of the chiral bicyclic ketone compound of formula (I) crystallizes in a crystalline form.Claim 33. The process of claim 32, wherein the recrystallizing solvent is acetone.Claim 34. The process of claim 32 or claim 33, wherein the anti-solvent is water.Claim 35. The process of any one of claims 32 to 34, wherein the recrystallization slurry is agitated with a wet-milling frequency, at a wet-milling temperature, for a wet-milling time.Claim 36. The process of any one of claims 33 to 35, wherein at least 50 wt% of the chiral bicyclic ketone compound of formula (I) crystallizes in the crystalline form, based on the initial amount of the dissolved chiral bicyclic ketone compound of formula (I).Claim 37. The process of any one of claims 33 to 35, further comprising:adding seed crystals to the recrystallization slurry,wherein the seed crystals are the chiral bicyclic ketone compound of formula (I) in the crystalline form.Claim 38. The process of any one of claims 33 to 37, wherein the crystalline form is characterized in that it exhibits one or more features selected from:a Amax absorption in the range of 700 to 720 cm-1when subjected to Raman spectroscopy as described in the specification;peaks of at least about 7.5° 20, about 8.2° 20, about 18.2° 20, about 20.0° 20, about 24.5° 20, and about 25.7° 20 when subjected to x-ray powder diffraction spectroscopy as described in the specification;the loss of no more than 0.5 wt% when subjected to thermal gravimetric analysis up to 150 °C as described in the specification; andan endothermic peak in the range of 159 to 162 °C when subjected to differential scanning calorimetry as described in the specification.Claim 39. The process of claim 30, wherein the crystalline form does not exhibit an endothermic peak in the range of 118 to 126 °C when subjected to differential scanning calorimetry as described in the specification.Claim 40. A process for the preparation of a chiral bicyclic ketone compound of formula (1-1):For a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce haloalkyl, phenyl, benzyl, 4 to 8 membered heterocyclyl and 5 to 6 membered heteroaryl, wherein R1is bound to the adjacent carbonyl by a carbon atom and R1is optionally substituted by one or two substituents selected from the group consisting of F, Cl, Br, Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce alkoxy, Ci-Ce haloalkyl, Ci-Ce haloalkoxy, hydroxyl, hydroxymethyl, phenyl, benzyl, CH2-(C3-C6 cycloalkyl), 5 to 6 membered heteroaryl, and CH2-(5 to 6 membered heteroaryl); each R4is selected from the group consisting of D, F, Cl, Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce alkoxy and Ci-Ce haloalkoxy;n is 1, 2 or 3;m is 0, 1, 2, or 3;the process comprising:(a) contacting a compound of formula (1-1):or a salt thereof, with a halogenating agent to form a compound of formula (III- 1):For a salt thereof,(b) contacting the compound of formula (111-1), or the salt thereof, with a first acid additive to form a compound of formula (IV-1 ):For a salt thereof;(c) contacting the compound of formula (IV-1) or the salt thereof, with an imidate compound of formula (V):(V)or a salt thereof, to form a chiral bicyclic triazole compound of formula (VI-1):or a salt thereof;(d) contacting the chiral bicyclic triazole compound of formula (VI-1), or the salt thereof with a compound R11-H, or a salt thereof in the presence of a basic additive to form a compound of formula (VI 1-1):or a salt thereof;(e) contacting the chiral bicyclic acyl compound of formula (VI I- 1 ), or salt thereof with an organometallic compound of formula (VIII):R1—M(VIII)to form the chiral bicyclic ketone compound of formula (1-1), or the pharmaceutically acceptable salt thereof;(f) dissolving an initial amount the chiral bicyclic ketone compound of formula (1-1) in a recrystallizing solvent to provide a recrystallization slurry; and(g) adding portions of an anti-solvent to the recrystallization slurry until at least a portion of the chiral bicyclic ketone compound of formula (1-1) crystallizes in a crystalline form.wherein:Pg1is H or a hydroxyl protecting group and may be the same or different on each occurrence;Pg2is a nitrogen protecting group and may be the same or different on each occurrence;R11is -NR51R52or 5- to 6-membered heterocyclyl optionally subsituted with one or more R6groups, whereinR51is H, Ci-Ce alkyl optionally substituted with one or more R53groups, or Ci- Ce cycloalkyl optionally substituted with one or more R54groups, R52is Ci-Ce alkyl optionally substituted with one or more R55groups, or Ci-Ce alkoxy optionally substituted with one or more R56groups, wherein each R53and R54is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; andeach R55and R56is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy;each R6is independently Ci-Ce alkyl, halide, -OH or Ci-Ce alkoxy; and M is lithium, MgX1, orZnX2, whereinX1and X2are each halide or R1, or a mixture thereof.Claim 41. The process of claim 40, wherein R1is cyclopropyl, n is i, and m is 0.Claim 42. The process of claim 40 or claim 41, wherein R11is:Claim 43. The process of any one of claims 40 to 42, wherein Pg2is Boc.Claim 44. The process of any one of claims 40 to 43, wherein the contacting a compound of formula (11-1) with the halogenating agent is performed in the presence of a solvent, an organic base and a fluoride source additive.Claim 45. The process of Claim 44, wherein the solvent is tetrahydrofuran, the halogenating agent is 5-chloro 2-pyridinesulfonyl fluoride, the organic base is trimethylamine, and the fluoride source additive is trimethylamine trihydrofluoride.Claim 46. The process of any one of claims 40 to 45, wherein the first acid additive is hydrochloric acid and toluene solvent.Claim 47. The process of any of claims 40 to 45, wherein each Pg1is ethyl.Claim 48. The process of any one of claims 40 to 47, wherein contacting the compound of formula (I V-1 ) or the salt thereof is in presence of ethanol, and the second acid additive is acetic acid.Claim 49. The process of any one of claims 40 to 48, wherein step (d) is in presence of methanol, and wherein the basic additive is lithium methoxide.Claim 50. The process of any one of claims 40 to 49, wherein contacting the chiral bicyclic acyl compound of formula (VII-1) or salt thereof is in tetrahydrofuran, and M is MgX1, and X1is bromine.Claim 51. The process of any one of claims 40 to 50, wherein the recrystallization solvent is acetone and the anti-solvent is water.Claim 52. The process of any one of claims 40 to 51 , wherein the recrystallization slurry is agitated with a wet-milling frequency, at a wet-milling temperature, for a wet-milling time.Claim 53. The process of any one of claims 40 to 52, wherein at least 50 wt% of the chiral bicyclic ketone compound of formula (1-1) crystallizes in the crystalline form, based on the initial amount of the dissolved chiral bicyclic ketone compound of formula (1-1).Claim 54. The process of any one of claims 40 to 53, further comprising:adding seed crystals to the recrystallization slurry,wherein the seed crystals are the chiral bicyclic ketone compound of formula (1-1) in the crystalline form.Claim 55. The process of any one of claims 40 to 54, wherein the crystalline form is characterized in that it exhibits one or more features selected from:a Amax absorption in the range of 700 to 720 cm-1when subjected to Raman spectroscopy as described in the specification;peaks of at least about 7.5° 20, about 8.2° 20, about 18.2° 20, about 20.0° 20, about 24.5° 20, and about 25.7° 20 when subjected to x-ray powder diffraction spectroscopy as described in the specification;the loss of no more than 0.5 wt% when subjected to thermal gravimetric analysis up to 150 °C as described in the specification; andan endothermic peak in the range of 159 to 162 °C when subjected to differential scanning calorimetry as described in the specification.Claim 56. The process of claim 55, wherein the crystalline form does not exhibit an endothermic peak in the range of 118 to 126 °C when subjected to differential scanning calorimetry as described in the specification.Claim 57. A compound, or a pharmaceutically acceptable salt thereof, prepared according to a process of any one of claims 1 to 56.Claim 58. A crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern with peaks of at least about 7.8° 20, about 8.8° 20, about 15.2° 20, about 17.5° 20, about 20.5° 20, about 23° 20, and about 25.7° 20.Claim 59. A crystalline form according to claim 58, having a Raman infrared spectrum with a Amax absorption in the range of 700 to 720 cm'1.Claim 60. A crystalline form according to claim 58 or claim 59, wherein the crystalline form exhibits a loss of no more than about 0.5 wt% when subjected to thermal gravimetric analysis up to 150 °C.Claim 61. A crystalline form according to any of claims 58 to 60, wherein the crystalline form having a differential scanning calorimetry endothermic peak in the range of about 159 to 162 °.Claim 62. A crystalline form according to claim 61, wherein the crystalline form does not exhibit a differential scanning calorimetry endothermic peak in the range of 118 to 126 °.Claim 63. A crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern as shown in “Form A” of Figure 2.Claim 64. A crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern with peaks of at least about 11.2° 20, about 13.8° 20, about 14.9° 20, about 17.6 ° 20, about 19.7 ° 20, about 20.3 ° 20, about 22.6 ° 20, and about 24.4° 20.Claim 65. A crystalline form according to claim 64, having a Raman infrared spectrum with a Amax absorption in the range of 730 to 740 cm'1.Claim 66. A crystalline form according to claim 64 or claim 65, wherein the crystalline form exhibits a loss of no more than about 0.6 wt% when subjected to thermal gravimetric analysis up to 150 °C.Claim 67. A crystalline form according to any of claims 64 to 66, wherein the crystalline form having a first differential scanning calorimetry endothermic peak in the range of about 118 °C to 126 °C and a second differential scanning calorimetry endothermic peak in the range of 159 °C to 162 °C.Claim 68. A crystalline form of cyclopropyl((5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methanone having an X-ray powder diffraction pattern as shown in “Form B” of Figure 3.